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ABSTRACT
Development of novel oral therapies for the treatment of inflammatory bowel disease
Shrey Kanvinde, Ph.D.
University of Nebraska Medical Center, 2018
Supervisor: David Oupický, Ph.D.
Inflammatory bowel disease (IBD) is a chronic and remittent inflammation of the
gastrointestinal tract (GIT). Despite extensive research efforts, there is no cure nor a welldefined pathogenesis for IBD. Loss of epithelial barrier function, increased colonic
immune cell infiltration and upregulation of pro-inflammatory cytokines are the
hallmarks of IBD. Despite treatments like painkillers, aminosalicylates, steroids, and
biologics, almost 70% patients require surgery at least once in their life time. The main
limitation with most of the current treatments is they are either absorbed systemically or
administered systemically resulting in adverse side effects. As a result, there is a huge
unmet need for therapies that can be safely and locally delivered to treat inflammation.
Chloroquine (CQ) has been used as an anti-malarial for a long time and recently it
has found anti-inflammatory applications. However, long term administration of CQ
results in severe side effects like retinopathy because of systemic absorption. In this
dissertation, we have re-designed CQ into a polymer (pCQ) and evaluated its potential as
an orally administered IBD therapeutic. We found that pCQ showed preferential
localization in the GIT which almost negligible systemic levels. We further evaluated the
anti-inflammatory activity of pCQ in a mouse model of IBD and found reduction in colon
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inflammation. We achieved this while reducing the systemic absorption almost 100 times
which translates into an increased safety profile.
We then assessed the effect of local delivery of combination of TNFα siRNA and
polymeric CXCR4 antagonist (PCXA) via chitosan (CS) nanoparticles (NPs) in vivo. We
found that the particles not only demonstrated a desirable size but also protected the
siRNA against biorelevant conditions which are usually encountered in the GIT. Our
results also indicate uptake of these particles by macrophages which are target cells and
infiltrated the inflamed colon tissue in IBD. We tested the particles in vivo in a mouse
model of colitis. We observed the therapeutic effect due to CXCR4 inhibition as well as
observed TNFα silencing in the colon.
Both these systems showed promise as local anti-inflammatory therapies.
However, further development is needed to enhance their anti-IBD potential.
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Chapter 1: Introduction
1.1 Inflammatory Bowel Disease
IBD is a collective term for a group of chronic inflammatory diseases affecting the
GIT. It majorly manifests itself in two forms – ulcerative colitis (UC) and Crohn’s disease
(CD). UC and CD can share many clinical characteristics, although they are considered
distinct inflammatory conditions. Chronic and relapsing mucosal inflammation is a major
characteristic of both UC and CD. UC affects the colon which is the terminal part of the
intestine. UC inflammation affects only the mucosa without affecting deeper tissue layers.
In UC, the inflammation usually extends proximally from the colon and is continuous but
confined to colon and rectum. Inflammation in CD can affect any region of the GIT and is
usually discontinuous. CD inflammation in transmural, meaning it affects the deeper
layers like muscularis and serosa as well. Other symptoms include intestinal swelling,
abdominal pain, diarrhea, blood in stool and weight loss. IBD has an annual healthcare
cost of over $1.7 billion in the United States. Despite extensive research efforts, the exact
mechanism of how IBD occurs is still unknown. Current research points out in the
direction that IBD is a result of a complex interplay between a variety of factors. Broadly
the factors can be classified as follows –
1.1.1 Genetics
There have been recent technological developments in DNA analysis and sequences in
conjunction with utilization of huge multinational databases [1]. This has led to many
groups exploring genetic contributions to IBD development. All these studies have
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identified 163 which are associated with IBD of which 30 are CD specific, 23 are UC
specific and 110 are associated with both the conditions [2]. NOD2 which encodes for a
protein recognizing MDP in bacteria was the first identified susceptibility gene for CD [3].
Stimulation of MDP induced autophagy and modulates the immune system. It also
participates in MDP-independent pathways like T-cell regulation. A genome-wide metaanalysis has already shown an association between NOD2 and development of CD [4].
Numerous studies have reported the effect of autophagy in IBD immune response
particularly two genes, ATG16L1 and IRGM [5]. Autophagy plays a role in intracellular
homeostasis by degrading and recycling cytosolic contents as well as intracellular
microbes. ATG16L1 mutations have been implicated in higher risk of IBD incidence [6].
IBD-associated polymorphisms in IRGM leads to reduced protein expression. Genetic
screen studies have identified the involvement of IL23R, JAK2, STAT3 in both UC and CD
[7]. Reported studies have proved that the expanding number of susceptibility gene loci
described in IBD is an indication that genetic influences are critical components of the
disease pathogenesis. However, explainable susceptibility loci discovered so far account
for only 20%-25% of the heritability found in the above-mentioned studies. This is not
only true for IBD, but also true for many other polygenetic diseases, and the phenomenon
has been called “the mystery of missing heritability of common traits” or “genetic
vacuum” [8]. New insights like gene-gene interactions, gene-pathway interactions and
gene-environment interactions may lead to more valuable information in IBD
pathogenesis than just focusing on finding new gene variants.
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1.1.2 Environmental triggers
Environmental factors play an important role in the pathogenesis of IBD. The
common environmental triggers include smoking, diet, drugs, geographical location,
social stress, and psychological element. Amongst all these, smoking is the most studied
and well-documented factor for IBD. In 1982, an inverse relationship between smoking
and UC development was reported [9]. Subsequently few reports confirmed the
protective effect of smoking on UC development where patients who were smokers had
a lower rate of relapse of inflammation. However, reports on CD described that smoking
increases the incidence of CD and correlates with higher rate of postoperative disease [10].
Many efforts have been directed at associating dietary excess or shortage of
various foods as a factor in incidence of IBD [11]. Most commonly, higher intake of
saturated fatty acids and monosaccharides, as well as low dietary fiber have been
associated with a higher risk of CD development [12]. Many studies have emphasized the
conflicting role of high intake of dietary monosaccharides on development of IBD. In
retrospective studies, CD patients who felt sick had a higher percentage of
monosaccharides in their diet [13, 14]. Russel and co-workers showed associated
consumption of cola and chocolate with higher incidence of IBD [15]. Their observations
were confirmed by Sakamoto and co-workers by demonstrating higher incidence of IBD
in patients who consumed sweets and artificial sweeteners [16]. Contrary to these
findings, Chan and co-workers conducted a large study having over 400000 volunteers
that reported no association between the intake of monosaccharides and the incidence of
either UC or CD [17]. Increased consumption of lactose was not reported to have any effect
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on the development of IBD [14]. Few reports also demonstrated a slight increased risk of
IBD development by excess consumption of animal protein. The same group also reported
that a high fat diet, especially rich in cholesterol and animal fats may increase the rate of
incidence of IBD [18]. These findings were corroborated by Ananthakrishnan and coworkers, who confirmed the effect of trans fatty acid consumption on UC development
[19]. Consumption of linolenic acid has been linked to development of IBD. This fatty acid
gives rise to arachidonic acid which is broken down into metabolites that exhibit proinflammatory properties [20]. John and co-workers carried out a study of over 25000
participants maintaining a 7-day food diary and demonstrated the protective effect of
unsaturated omega-3 fatty acid intake on the occurrence of UC [21]. Many studies have
reported that high fiber consumption reduces the risk of IBD up to 40% [22]. Vitamin D
deficiency is commonly observed in IBD patients. As such, few researchers believe this
deficiency to be a dietary factor that may increase the incidence of IBD. Increased intake
of fruit whole or as fruit juice especially with Vitamin C has been implicated in reduced
risk of IBD development [23]. No correlation between alcohol intake and IBD
development has been observed [24]. Looking at the overall literature, dietary factors play
an underestimated role in the development of IBD. Following a certain diet maybe of
advantage in reducing the incidence of IBD, especially for individuals already affected by
such conditions. This might help in achieving or maintaining stages of remission and
improving the overall quality of life. However, there is no single specific diet for IBD
patients, so dietary recommendations can be used in supplement to therapy [25].
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According to ecological and epidemiological evidence, air pollution may play a
role in the incidence of IBD as well. Countries with higher development of
industrialization have shown an increase in the incidence of IBD [26]. Increase in pollution
levels correlates with an increase in circulating polymorphonuclear leukocytes and
plasma cytokines [27]. Overall, environmental factors represent a gray area in IBD
pathogenesis. Multiple explanations have been reported describing the interactions of
environmental factors with the components of immune system resulting in an abnormal
inflammatory response, however, none of the explored factors have convincingly
described the pathogenesis of IBD [28]. Thus, further studies are needed to explain the
role of environmental determinants of IBD.
1.1.3 Microbial factors
The GI environment is rich in microorganisms. About 1011-1014 microorganisms
which contain 300-500 bacterial species are reported to be present in the gut [29]. In
healthy individuals, bacteria play an important role in intestinal homeostasis. The role of
gut bacteria in nutrition, immune development and energy metabolism has been
elucidated [30]. Majority of the gut bacteria are gram-negative with minor population of
gram-positive bacteria [31]. The diversity and the number of the gut microbiota are
severely affected during presence of inflammation [32]. Almost 25% less genes were
detected in the feces of IBD patients compared to healthy individuals [33]. There are
multiple indications that bacteria may play a role in the development of IBD, as evidenced
by the effectiveness of antibiotics in some IBD patients [34]. Secondly, IBD patients have
increased antibody titers against bacteria which are present in gut under normal
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conditions [35]. The genetic parameters associated with bacterial detection like NOD2 and
T cell immunity are implicated in IBD [36]. Lastly, most of the animal models of IBD need
luminal bacteria for initiation of inflammation [37]. To date many pathogens have been
assessed as causative agents for IBD pathogenesis. Reduction of phyla Firmicutes is a welldefined change that has been reported by multiple metagenomic studies [32, 38]. Analysis
of the fecal microbiome showed reduction in anti-inflammatory microbiota and an
increase in the pro-inflammatory microbiota [39]. Most known pathogenic bacteria in the
human GIT belong to phylum proteobacteria [40, 41]. Adherent-invasive E. coli has been
reported in multiple studies. AIEC usually invades the epithelium and replicates in the
macrophages [42]. AIEC has been detected more frequently in patients with IBD
compared to healthy individuals [43]. Similar observations have also been made for
Campylobacter concisus, Clostridium difficile and few other bacteria [44, 45]. Although, all
this data suggests the potential role of bacterial imbalance might play a role in IBD
development, no study has pointed out whether these changes are causative in IBD or just
a consequence of the alterations in the GI environment during inflammation. Thus, further
studies which point out the response of the gut microbiota to various other factors are
needed to strengthen the role of the microbiota in the development of IBD.
1.1.4 Immunological factors
The role of mucosal immunity, especially T cell response has been studied for a
considerable time in IBD pathogenesis. There is evidence that imbalance between the
innate and the adaptive immune pathways plays a role in the erratic immune response
observed in IBD. Adaptive immune response has been the focus of many pathogenesis
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studies in IBD and lead to the conclusion that CD is driven by a Th1 response while UC
has been associated with an unconventional Th2 response. Innate immune response has
been recently studies and has been associated with epithelial barrier integrity, innate
microbial sensing and unfolded protein response.
Innate immunity forms the first line of defense against pathogens which is often
non-specific and allows the body to respond quickly to stimuli usually within minutes. It
is mediated by epithelial cells as well as immune cells. This response is initiated by
microbial pattern recognition receptors present on cell surface called TLRs and NOD-like
receptors in the cytoplasm. Studies have found the behavior and expression of both these
receptors to be significantly altered in IBD patients. Neutrophil accumulation, IL-1β and
IL-8 production was reduced in IBD patients. Studies have revealed that mutations in
NOD2 which are associated with CD affect the ability of the gut to response to LPS
contributing to disease development. Although controversial, available reports point the
role of NOD2 mutations in reduced activation of NF-κB as well as development of
tolerance. IL-23 represents a key cytokine in immune responses against pathogens.
Polymorphisms in IL-23 gene have been reported to play a role in both UC and CD. The
epithelial barrier represents the second line of defense against the invasion by bacteria.
Increase in the intestinal permeability and loss of the epithelial barrier has been observed
in IBD. Mucus layer which covers the epithelium represents the first barrier against
microbes. The cells which constitute the epithelium also secrete many anti-microbial
peptides. The expression of these peptides has also been to be altered in IBD patients. The
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role of the adaptive immune system in IBD development is still undergoing extensive
research.
1.2 Current treatment strategies and challenges
Therapy options which are currently utilized include conservative measures as
well as surgical procedures for patients who do not respond to treatment. Traditionally,
the goal of IBD therapy has been to alleviate the symptoms of the disease and prolong
remission. Many drug- as well as patient related factors influence the treatment of IBD.
Drug-related factors include PK and PD, while patient-related factors include severity of
disease, location of inflammation and responsiveness to treatment. Due to the absence of
a permanent cure and the chronicity of the disease, patients essentially must be on
treatment life-long [46]. Presently, a wide array of drugs both conventional and novel are
available for treatment of IBD. Despite this, almost 80% of patients require surgery due to
failure of therapy [47]. Current treatments for IBD can be divided into five main categories
(Fig. 1) which are described as follows1.2.1 Anti-inflammatory drugs
Anti-inflammatory drugs are one of the earliest therapies which were used for the
treatment of IBD. To date they represent one of the most frequently used therapy options
in patients with ulcerative colitis. Aminosalicylates form a majority of this class of drugs.
5-ASA usually recommended as the first line of therapy for mild to moderate IBD. It is
usually used as an oral or rectal formulation. Pro-drugs such as sulfasalazine, balsalazide
are also available [48]. Aminosalicylates mainly function by inhibition of lipoxygenase
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and cyclooxygenase pathways which are involved in metabolism of arachidonic acids
which are the precursor of eicosanoids and downstream inflammatory cytokine signaling
[49]. Patients who do not respond to aminosalicylates are usually treated with
glucosteroids and corticosteroids [50]. Both these classes affect the immune and
inflammatory responses, and function by reducing pro-inflammatory cytokines [51].
1.2.2 Immunosuppressants
Patients with severe IBD who are unresponsive to corticosteroid therapy are
usually treated with immunosuppressive agents like cyclosporine or MTX. Most of the
drugs of this class have been used in other diseases and cancers way before they were
used for treatment of IBD. MTX is a folate analog and an inhibitor of DHFR [52]. It
interferes with synthesis of DNA and exhibits anti-inflammatory effects including
reduced production of pro-inflammatory cytokines and lymphocyte apoptosis [53].
Clinical trials for oral and IM therapies have been conducted. MTX showed significant
improvement in IBD patients. MTX also maintained remission in patients [54]. However,
MTX group also suffered more side effects which were nausea or liver test abnormalities
[55]. Patients who are steroid dependent for remission are treated with azathioprine and
mercaptopurine. Both these drugs are purine analogs and are converted to active
metabolites that interfere with nucleic acid synthesis, lymphocyte proliferation. They have
been studied in the treatment of IBD since 1960s, with multiple trials showing promising
effects. However, most of the trials indicated that therapy with AZA or 6-MP would be
usually for an indefinite amount of time for responding patients. Although effective in
induction and maintenance of remission, long term usage of these drugs leads to
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development of pancreatitis and leukopenia. As a result, the use of this medication is best
coupled with another regimen like steroids.
1.2.3 Biologic agents
This class represents the newest and one of the most clinically used therapeutics
which directly targets the main features of inflammation. Antibodies against upregulated
pro-inflammatory cytokines form a major part in this group. TNFα is a potent mediator
of inflammation which is commonly upregulated in the intestinal mucosa of IBD patients
[56]. It is one of the late-stage cytokine of inflammatory cytokine cascade. It has been
reported to play an important role in the development and progression of the disease. As
a result, TNFα neutralization has been an extensively explored therapeutic strategy in
various inflammatory disorders [57]. TNFα antibodies have been the most successful
clinically translated biologic therapy for IBD.
Infliximab is a human chimeric monoclonal antibody which is a genetically
constructed IgG1 murine antibody binding to both the soluble and the membrane-bound
TNFα [58, 59]. It has been successful in the induction as well as remission maintenance of
CD and UC [60, 61]. Adalimumab and Certolizumab are both TNFα antibodies which
have been clinically approved for IBD therapy. Improvement in TNFα antibodies have
also been made by modifying their structure. Certolizumab pegol is a pegylated, Fab’
fragment of a humanized monoclonal antibody which binds TNFα [62]. The pegylation
improves the stability and enhanced the circulation time in the body leading to reduction
in dose [63]. It has shown better remission rates as compared to other antibodies on market
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[64]. It does not contain Fc portion and consequently does not show cellular cytotoxicity
[65].
Despite being successful, these therapies have face many limitations.
Immunogenicity is observed in some patients as they develop antibodies against the
monoclonal agents. The development of immunogenicity usually occurs through both
thyroid-dependent and thyroid-independent mechanisms [66]. These anti-drug
antibodies are usually IgG antibodies that hinder the binding of monoclonal therapeutic
to its target cytokine or increase the rate of excretion via RES [67]. Almost 60% patients
were reported to develop anti-drug antibodies against infliximab [68]. As a result, the dose
of infliximab has been optimized which has lowered the prevalence of anti-infliximab
antibodies to 10-20% in clinical trials [69]. However, in this patient population, loss of
clinical response and rise of infusion reactions has been observed once they develop antiinfliximab antibodies [70]. Another limitation, majorly because of the systemic silencing
of TNFα is the development of immunosuppression, which predisposes these patients to
opportunistic infections and development of colon cancer [71]. Development of active TB
with infliximab has been documented [72]. As a result, approaches other than targeting
inflammation through cytokines have also been explored [73]. Such therapies can be used
in conjunction with anti-TNFα therapies to improve the therapeutic outcomes in IBD
therapy or for treating patients who are refractory to anti-TNFα therapies. One such
strategy which has attracted significant attention is anti-adhesion therapy [74]. IBD
involves extensive lymphocyte trafficking from the circulation which interact with the
endothelial cells using adhesive interactions [75]. The proteins involved in these
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interactions represent attractive targets for developing new therapeutic strategies for
controlling inflammation in IBD. Antibodies against adhesion molecules and integrins
have been developed. Natalizumab is developed against anti-α4 integrin to reduce
lymphocyte migration into the intestinal mucosa [76]. However, since this antibody was
not specific to the intestine, there were concerns with development of PML leading to
decline in its use [77]. This antibody became a building block for this concept and led to
development of similar future drugs. First drug from the second-generation drug includes
“gut selective” vedolizumab. It is an anti-α4β7 antibody that shows gut specific
immunosuppression. Clinical trials have not only indicated the efficacy but also reduced
risk of PML with vedolizumab leading to approvals from FDA and EMA [78]. Similar gut
selective antibodies like etrolizumab (anti-β7 integrin) and PF-00547659 (anti-MadCAM-1)
have been developed and undergoing clinical trials [79, 80]. AJM300 is a recently
developed oral α4 integrin antagonist [81]. It has concerns with development of PML,
however, a discontinuous therapy with this agent is possible because of its short half-life
(daily dosing of three times) providing a possible strategy if PML were to occur [82].
There are other newer generation biologic drugs in phase III clinical trials.
Ustekinumab is an antibody against IL-12/23 which has been clinically approved and used
for treatment of psoriasis and arthritis [83]. Its potential in treatment of IBD is being
studied. Another class of upcoming biologic drug includes Tofacitinib which is a JAK1
and JAK3 inhibitor [84]. A novel aspect of this drug is that it has been developed for oral
administration. It has been approved for rheumatoid arthritis and is under clinical trials
for treatment of IBD.
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1.2.4 Antibiotics
The GI ecosystem contains many bacteria, the composition of which changes with
time, age, diet and geography [85]. Although a causative species has not been pointed out,
there is plenty reports confirming the involvement of the GI microbiota in the
development of inflammation in IBD [86]. No IBD development is observed in genetically
engineered murine models that are raised in germ free environment but occurs when
bacteria are introduced in the intestines. As a result, manipulation of the GI microbiome
has been explored as an anti-IBD strategy [87]. Antibiotics can be used to control the
inflammation by decreasing the bacterial population in the lumen and changing the
composition of the intestinal microbiome to favor beneficial bacteria [88]. Antibiotics are
usually used prophylactically in IBD treatment [73]. Few clinical trials have tested
commonly used antibiotics like macrolides, fluoroquinolones, 5-nitroimidazoles and
rifaximin either individually or in combination [34]. All the studies revealed significant
benefits. Similar benefits were also observed in studies with ciprofloxacin and
metronidazole in CD [89]. These studies even revealed that antibiotic treatments induced
remission. However, the limitation with the use of antibiotics is the presence of many
sources of variation. Other than patient-related factors, various antibiotics have different
antibacterial spectrum. As a result, it becomes confusing to analyze data from trials which
involve a combination of antibiotics. Additionally, antibiotics have side effects that they
induce. Ciprofloxacin causes tendonitis and photosensitivity [90]. Metronidazole causes
GI distress and peripheral neuropathy if used long term [91]. Antibiotics may also cause
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a rebound effect in GI bacteria after the therapy is stopped leading to relapse [92].
Antibiotic resistance development is another limitation [93].
1.2.5 Symptomatic relief agents
Underlying mechanisms and pathophysiology of IBD have received significant
attention. However, the absence of a solid causative mechanism makes treatment
confusing. Surprisingly, there has been very few reports about the various symptoms that
are experienced by IBD patients. One survey study reported that a significant number of
patients experience diarrhea, fatigue, abdominal pain, joint ache and night sweats [94].
Presence of blood or mucus in stool was reported to be more prevalent in UC patients
compared to CD patients. Even in phases where the patients were reported to have
inactive disease, they still experienced the symptoms. Other than physical symptoms,
almost half the patients experienced stress [95]. Most common reported stress was family
stress followed by work and financial stress. However, it is difficult for clinicians to
associate stress with the presence of symptoms as feeling stressed with the presence of
symptoms is common. The reports on correlation between the pharmacological and
psychological parameters in IBD is limited. As a result, this area needs better research.
The current symptomatic treatment focuses on management of pain and diarrhea.
Acetaminophen is widely used in place of NSAIDs that have been considered as a
potential cause of flares in IBD [96]. For more advanced pain relief, narcotics have been
prescribed. However, their use is very minor as they are associated with increased risk of
mortality [97]. Common anti-diarrheal drugs used in IBD include loperamide,
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diphenoxylate, codeine and cholestyramine. Loperamide has been used most extensively
in a postoperative setting. Clinical trials have proved the efficiency of this drug in
managing diarrhea during IBD [98]. GI side effects as well as effects on normal physiology
of the GIT were less as compared to placebo group [99]. Based on the no reduction in the
defecation frequency and occurrence of side effects, many studies reported that
diphenoxylate has no place in the management of IBD symptoms. Looking at the bigger
picture, it is observed that a clinician’s decision about the treatment is still influenced by
the patient’s symptoms [73]. Symptomatic relief therapies will always be needed even
though a more pathophysiology based therapy is developed at some point of time. Thus,
finding treatments that can manage abdominal pain and diarrhea with less side effects are
needed. At the same time, assessing the efficacy of both psychological and
pharmacological interventions in IBD is needed.
1.3 Need for oral therapies for IBD
As described in the previous section, majority of the current therapies in IBD are
administered parenterally. Long-term dosing is needed in a chronic condition like IBD
and these therapies, in the long run show severe side effects. As a result, the payoff for all
these drugs comes at a huge risk. This has resulted in an unmet need therapies that act
locally in the colon, at the site of inflammation. Oral route of delivery is an attractive
option for delivering anti-inflammatory agents where the inflammation is local. In
addition to its traditional advantages like ease of administration, it also offers a route to
deliver the treatment directly to the site of action with minimal non-specific exposure.
Rectal route is another interesting avenue. However, it is difficult to target discontinuous
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inflammation or inflammation in the proximal part of the GIT with the rectal route. In
case of oral administration, with appropriate modifications in the delivery system, a local
effect as opposed to a systemic effect can be achieved. This will limit all the systemic side
effects while allowing safe and prolonged dosing regimens.
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Figure 1. Options for treatment of IBD (Adapted from [52])
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1.4 Challenges in oral delivery for IBD treatment
Despite being a promising route of administration, oral delivery to the colon
presents its own challenges. The major challenge being that it relies on a number of
physiological factors to achieve optimal drug concentration at the site of action, to make
sure therapeutic efficacy is achieved. The physiological conditions in the colon of an IBD
patient vary significantly from those in a healthy individual. The changes which occur in
the GIT during inflammation are highlighted in this section (Fig. 2). They form an
important consideration in the formulation of systems intended to deliver therapeutics to
the colon.
1.4.1 Transit time
In humans, colonic transit time is usually 2 to 6 hours. However, gastric and
colonic time in IBD patients vary significantly compared to healthy individuals. This is
mainly due to the presence of diarrhea which is very common in IBD patients. Colonic
transit times in IBD patients have been reported to range from 6 to 70 hours. This
represents a significant hurdle in determining the time of dosing with respect to bowel
movements. Changes in the transit time have been reported to significantly impact
targeting specific regions of the colon using conventional formulations as the drugs show
higher retention in the proximal GIT as compared to the colon.
1.4.2 pH
There are very few reports indicating any changes in the small intestinal pH in IBD
patients. However, colonic pH is significantly acidic in both UC and CD patients. pH in
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colon is influenced by many processes like microbial fermentation, metabolism of fatty
acids by bile, various secretions, intestinal volume and transit times. Since all the
parameters are disrupted during IBD, changes in the colonic pH are not unexpected. pH
in the colon ranges from 6.8 to 7.2 from proximal to distal colon, respectively. These values
can significantly differ in patients with IBD with the reported values being in the range of
5.5 to as low as 2.3, irrespective of the stage of the disease [100, 101]. These changes in the
pH affect the composition of the colonic microbiome and well as the transit times. This
can alter the behavior of formulations which are enzymatic or pH-dependent for release
of drugs.
1.4.3 Intestinal volume
The composition of intestinal luminal contents varies significantly in IBD patients
compared to healthy individuals. These changes directly impact the transit time as well
as the pH conditions. Higher fluid secretion leads to dilution of the enzymes that play a
vital role in absorption through the colon. This may also alter the composition of the
intestinal flora which alters the digestion of carbohydrates leading to changes in transit
times. These changes can affect the way conventional formulations are processed in the
GIT and create hurdle to local delivery of drugs.
1.4.4 Histological changes
The intestinal epithelium represents one of the most selective barriers in the
human body. It regulates the transport of the luminal contents into the tissue. Small
molecules are restricted selectively while macromolecules are not transported. While this

20

barrier seems to be an attractive target that can be manipulated to achieve selective
absorption of drugs, epithelial integrity is lost in IBD. Inflammation not only disrupts the
barriers but also affects the individual cell types. Significant crypt damage as well as loss
of the intestinal brush border affects the uptake and absorption properties of the
epithelium. There is loss of goblet cells which are responsible for mucus production which
results in thinning of the mucus layer which usually represents the first barrier to reach
the tissue. This affects the permeability of lipophilic drugs and mucoadhesive systems.
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Figure 2. Physiological changes in the GIT in IBD. (adapted from [102])
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1.5 Applicability of oral particulate delivery systems in colonic inflammation
As discussed previously, the current treatments for IBD are largely limited due to
their systemic side-effects. With the biologic therapies like antibodies, development of
resistance and immunosuppression are other concerns. With a view to overcome the
limitations of traditional small molecule drugs for IBD, sustained-release drug delivery
systems like capsules and enteric coating tablets have been developed for release drugs
specifically in the colon. These delivery systems minimize the absorption of drugs in the
upper GIT by releasing active agents influenced by colon specific conditions such as pH,
enzymes, etc. However, as discussed in preceding section, the colonic conditions in the
presence of active inflammation vary significantly compared to healthy colon. Interpatient variability is another confounding factor. Consequently, current macroscopic
delivery systems lack specificity to target only the inflamed parts [103]. Furthermore,
about 90% of the IBD patients experience diarrhea which results in rapid intestinal
clearance of these delivery systems, compromising their efficacy. To circumvent the
limitations of the current macroscopic delivery systems for IBD, many groups have
focused on utilizing particulate delivery systems. In 1998, Rein and co-workers laid down
a hypothesis stating that the disruption of the intestinal barrier at the inflamed colonic
regions could allow preferential accumulation of particles in those areas. Additionally,
the accumulation of macrophages and dendritic cells at the inflammation site could result
in higher uptake of particles. A size-dependent deposition study of fluorescent
polystyrene microparticles and nanoparticles in an experimental model of colitis was
carried out as a step in the direction towards this strategy. Higher adhesion of particles
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was observed at the layers of inflamed tissues which had more mucus while in the
ulcerated areas, a size dependency was observed. Targeting to inflamed areas became
more effective with smaller particles. Particles in the submicron sizes showed higher
uptake by macrophages and could evade clearance by diarrhea which is a common
symptom of IBD. Encouraged by these studies, many groups started using particulate
systems to encapsulate drugs or biologics to create more applicable and complex
treatment strategies for IBD therapy which were either dependent on their size or
harnessed a colon-specific target for accumulation. The following part reviews
development of some of these systems according to their driving stimulus.
1.5.1 Size dependent systems
Particle size reduction to the nanometer scale has been shown to improve the
accumulation of nanoparticles in the inflamed colonic areas thus a promising finding for
IBD therapy. The size reduction allows for enhanced and specific delivery of active
principles in inflamed tissue via an epithelial enhanced permeability and retention effect
while allowing selective uptake by the immune cells that accumulate in these areas [104].
Accumulation in the inflamed tissue increases the local concentration of drugs which is a
useful parameter for IBD therapeutics. Reduction in the size also helps particles escape
quick clearance due to diarrhea [105]. NPs can undergo internalization by paracellular
transport, transcytosis through M cells and through gaps in the intestinal villi [106, 107].
There have been numerous reports which look at particle deposition as well as uptake in
inflamed colon based on their size. Highest binding to inflamed colon mucosa was
observed with 100nm particles when polystyrene particles ranging from 0.1 to 10 µm were
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orally administered for 3 days in TNBS colitis model in rats [108]. However, after washing
off the mucus there was a significant reduction in the particles suggesting high proportion
of particles getting entrapped in the mucus rather than being taken up by immune cells.
This effect was observed independent of the particle material as a number of studies
showed similar effect with various non-functionalized particles [109]. A comparative
study between NP and microparticle uptake into rectal mucosa in human IBD patients
showed that microparticles accumulated to a higher extent while only trace amounts of
NPs were detected [110]. Although the microparticles showed enhanced bioadhesion and
accumulation, there was negligible absorption across the epithelial barrier. On the
contrary, NPs were found to be transported to the serosal compartment indicating
microparticles might be a more suited drug delivery vehicle for local colonic application
in humans. There is no explanation for the opposite observations for the effect of particle
size on colon accumulation between animals and humans. While a glance at the reported
study suggests that a reduction in particle size is essential for accumulation in the colon,
there is no proof that that non-functionalized particles show specific accumulation in the
inflamed versus the healthy parts of the colon in vivo. As a result, other strategies for
enhancing the accumulation in inflamed regions including surface modification have
been studied.
1.5.2 Surface charge dependent systems
Very few reports have been published about the effect of physicochemical
properties other than particle size on the adhesion and accumulation of particles in the
inflamed colon tissue [111]. The effect of surface charge on binding to inflamed tissue has
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been reported mainly through ex vivo studies or in vivo studies with rectal administration
with conflicting conclusions. Surface charge modification should theoretically improve
selectivity towards inflamed tissue by influencing the electrostatic interactions between
the particles and the tissues. Additionally, binding of surface charged modified particles
to other components in GIT like bile acids during transit is another concern. Thus,
additional pharmaceutical strategies are needed, in conjunction with surface charge
modification to achieve localized drug delivery to the inflamed tissue.
Many studies have revealed improved deposition and therapeutic efficiency in
IBD of particles having a positive surface charge. Cationic systems adhere to mucosal
surfaces because of interaction between the nanocarrier and the negatively charged
mucosa [112]. Mucins which form a major portion of the colonic mucosal surface possess
a negative charge as most of their carbohydrates are substituted with sulfate and sialic
acid residues [113, 114]. As a result of their charge interactions, most of the cationic
materials possess mucoadhesive properties. Adhesion can be a desirable as it can promote
more interaction between the mucosal surface resulting in higher particle uptake as well
as reduced clearance in the presence of diarrhea, which is common in IBD. In CD, there is
an increase in mucus production leading to a thicker mucus layer in the inflamed regions,
making mucoadhesion an attractive strategy to enhance specificity and retention of
delivery systems in those areas [115]. One of the most frequently used cationic polymer
especially in oral delivery systems is CS. CS-functionalized PLGA NPs were reported to
adhere onto human intestinal mucosa ex vivo [116]. However, very less uptake in the
tissue was observed for both inflamed and healthy areas probably due to strong
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association with the negative mucosal surface. This finding has also been supported by
other reports which used TMC, a derivative of CS [112]. As a result, this approach might
be effective in delivering drugs which act on extracellular domains [102].
Anionic systems have been developed with a goal to target positively charged
proteins like eosinophil cationic protein and transferrin which are overexpressed in colons
of IBD patients [117]. Such systems are able to diffuse through the mucus layer due to less
association with the negative charge [118]. When compared ex vivo, anionic liposomes
showed two-fold higher adhesion to inflamed tissue as compared to cationic and neutral
liposomes [119]. The adherence was in direct proportion to the negative charge density.
However, only limited conclusions can be drawn from such studies as the conditions in
vivo might differ significantly.
Drawing from these studies, it is not very clear as to how the size or the charge
affects the adhesion, uptake and absorption of the particles. As a result, an additional level
of control and complexity has been added by synthesizing delivery systems that utilize
physiological changes that occur during the course of GI transit or during inflammation.
1.5.3 pH- dependent delivery systems
These delivery systems make use of the difference in pH in different regions in the
GIT. The pH in the GIT varies from highly acidic in the stomach to almost neutral in the
ileum and the colon. As a result, a delivery system that disintegrates at colonic pH can
provide colon-specific delivery. Traditional delivery systemic like tablets and capsules
have been utilizing enteric coatings to create delayed release of drug in the colon to
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achieve specific delivery [120]. One of the most used pH dependent polymers are
methacrylic acid copolymers, commercially known as Eudragit. In addition to pH
dependence, Eudragit polymers also show mucoadhesion.

Innovating from these

conventional dosage forms, many studies have been reported where such polymers have
been adopted to form nano-delivery systems. Liposomes coated with Eudragit have
shown superior mucoadhesion in pig intestine compared to other polymer coatings [121].
Although showing favorable release kinetics which were colon specific, this system was
shown to degrade when incubated in the presence of bile salts which would hinder its
application in vivo [122]. This led to development of pH dependent colon specific
polymeric nanocarriers for IBD treatment. Budesonide loaded particles made up of PLGA
and Eudragit S100 mixture showed superior anti-inflammatory effect than conventional
enteric coated microparticles [123]. Similar system was applied and used for developing
nanocapsules [124]. Nanocapsules showed a higher loading capacity for lipophilic drugs
as they have a polymeric wall around a core [125]. Both these systems also showed colon
specific release. These systems have also been tested and reported for their ability to
reduce inflammation in various animal models. Although promising in preclinical testing,
pH-dependent nanocarriers face hurdles in their clinical translation because of the inter
as well as intra-patient variability in pH that is observed in IBD. As a result, a system
which solely depends on pH difference in the GIT might not be reliable for IBD therapy.
1.5.4 ROS-responsive delivery systems
These delivery systems utilize high levels of ROS which are commonly observed
in the inflamed tissue. Usually high concentrations of ROS are localized only to sites of

28

inflammation due to the accumulated phagocytes [126]. Although the concept of ROSresponsive delivery systems is relatively old, very few oral delivery systems have been
developed which utilize it for treating inflammation, mainly because it necessitates the
synthesis of novel materials which can be fabricated into nanocarriers. One such example
are TKNs which were formulated from PPADT which degrades in presence of ROS [127].
This material was used to encapsulate TNFα siRNA complexed with a cationic lipid to
form NPs. These particles showed selective accumulation in the inflamed colon areas in
vivo. These particles were also shown to significantly reduce inflammation and
inflammatory cytokines as compared to controls. Another system which utilized ROS was
designed to mimic SOD/ catalase enzyme system which actively neutralizes ROS
generated in the body [128]. This system degraded specifically in the presence of
superoxide which is a major ROS in the body and reduced inflammation by neutralizing
over produced ROS in vivo in the colon.
1.5.5 Actively targeted delivery systems
With the advent of systems that are colon specific, researchers have started looking
into developing delivery systems that can deliver therapeutics specifically to the inflamed
regions of the GIT. Such systems use ligands decorated on the surface of the particles to
actively achieve specific accumulation in the inflamed areas to deliver therapeutics and
get an enhanced anti-inflammatory effect [129]. The strategy is based on the concept that
the ligand-receptor interaction expressed specifically at the inflammation sites will
improve the accumulation of the formulation on those areas. The ligands are selected to
harness various inflammation-induced changes like receptor or protein expression in the
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tissue. This approach has been vastly used for developing parenteral delivery systems to
target diseases like cancer and infections [130]. Encouraged by the success of these
systems, many researchers have attempted this approach to develop orally administered
particulate systems. Commonly used targeting moieties include monoclonal antibodies
and peptides as they exhibit high targeting specificity [131]. However, development of
formulations which utilize these targeting moieties is a challenge as they are labile to
gastric acid as well as enzymes. Many targeting moieties have been tested for oral colon
inflammation-specific drug delivery. The first proof of concept study utilized polystyrene
nanoparticles coated with anti-ICAM-1 antibodies. The biodistribution and uptake of
these particles, following oral administration was assessed in vivo using fluorescence and
radiolabeling [132]. Almost 60% of the administered antibody dose was degraded, these
particles showed targeting predominantly in the upper GIT. Although ICAM-1 is
overexpressed on the surface of inflamed mucosal tissues, this study was not performed
in an animal model of colitis [133]. Macrophages infiltrate the inflamed colon tissue in
IBD. As a result, mannose receptors and MGL which are overexpressed by the
macrophages under inflammatory conditions [134]. Bioreducible mannosylated cationic
polymer which could complex siRNA by electrostatic interactions to form ~250nm NPs
showed significant macrophage targeting ability [135]. The uptake was shown specifically
by macrophages and not by epithelial cells showing that the targetability was because of
the mannose. A similar system comprising of PLGA NPs grafted with mannose showed
high accumulation ex vivo in inflamed areas of the colon. However, both these studies did
not assess the accumulation in an in vivo model of colitis. A galactosylated trimethyl
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chitosan-cysteine NP system complexed with Map4K4 siRNA was developed to target the
MGL on the macrophages [136]. This system showed significantly higher uptake in
macrophages compared to control NPs proving the effect of galactose receptor-mediated
endocytosis. This system demonstrated significant reduction in inflammation in DSSinduced colitis mouse model. Based on the same concept various other systems which
achieve targeting through Fab’ portion of a macrophage specific ligand and other
receptors like transferrin, CD98 have been developed and reported [137]. Not only
polymeric nanoparticles but also liposomes and hydrogels have been actively targeted to
inflamed areas in the colon.
1.6 Conclusion
In the following chapters, I will present the most important findings on the
development of oral therapies for IBD treatment and the studies related to their
physicochemical characterization and biological testing. The characterization and the
validation studies we performed to assess the suitability of the animal models we have
used in this dissertation are describe in chapter 2. Chapter 3 describes alteration of the PK
of chloroquine using a PDC to make it more suitable for oral delivery for local treatment
of inflammation. Chapter 4 explores the physicochemical testing and therapeutic effect of
polydrug/ siRNA combination in IBD treatment.
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Chapter 2: Characterization of animal models for suitability
2.1 Introduction
As discussed in the previously, IBD is a chronic and debilitating disorder. It is the
result of complex interplay between various immunological, genetic and environmental
factors. This has led to many groups have tried to elucidate the mechanism of
development of IBD using a variety of in vitro studies because of the ability to control
various causative factors independently. However, the complexity of the disease has
negated all the advances in the study of IBD leading to a lot of fundamental gaps in our
knowledge. A great deal of information about other human diseases as well as design of
therapies has been carried out on the basis of studies carried out in animal models [138].
However, one of the problems with understanding the pathophysiology as well as
designing therapies for IBD has been attributed to the lack of suitable animal models. An
ideal model of IBD would be a disease in an animal that is identical in every factor to
human IBD [139]. This would ensure that the animal model has similar pathological
features as well as response to experimental treatments. In addition to this, the animal
model also must be amenable to experimental manipulation to study disease progression
and pathogenesis. Currently used IBD animal models are broadly categorized and their
advantages and limitations are mentioned in the table below-
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Table 1. Currently used IBD animal models (Adapted from [140]).
Category

Model

Advantages

Disadvantages

Chance to identify the role of
specific genes, target specific
cells

Reduced
pathologic
relevance as human
IBD rarely has
single gene
mutation

Disease with multifactorial
causes which increases
pathogenic relevance

Poor breeding
ability, high cost
for colony
maintenance

Easy induction, inexpensive

Lack of
reproducibility,
varying protocols,
overlooks
pathogenic factors
associated with the
human disease

IL-2 KO
IL-10 KO
Gene
knockout

T cell receptor
mutant
TNF-3’ UTR
KO

Transgenic

IL-7 TG
C3H/HejBir

Spontaneous

SAMP1/Yit
Acetic acid
Iodoacetic acid

Inducible

TNBS
DSS
Oxazolone
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As described in the table, there have been many animal models of intestinal
inflammation but the definition of an ideal model exposes many problems which spring
from huge fundamental gaps in our knowledge on IBD. No single model captures all the
complexities of human IBD, but takes into consideration only a particular major aspect of
the disease. As a result, the animal models currently used are more of models of intestinal
inflammation rather than IBD models. Another major challenge in testing novel oral drug
delivery systems in IBD is mimicking the GI environment in vitro, particularly because of
the diversity in the pH, enzymes and mucosal surfaces [101]. Despite having many
limitations, the current animal models offer a lot of choices can give insight not only into
how the GI environment changes during inflammation but also whether new therapeutic
candidates may show promise in IBD-like disorders. As a result, from the perspective of
developing and testing novel therapeutic candidates, it is not only essential to characterize
the suitability of the animal model based on its pathophysiology but also for potential
interactions between the inflammation inducing agent and the drug delivery system. In
this chapter we discuss the characterization of DSS and the C. rodentium induced mouse
models we performed to assess their suitability to our studies.
2.2 Materials and Methods
2.2.1 Materials
CaCO2 cells, CL antibodies and DAPI mounting medium were obtained from Dr.
Amar Singh’s lab, DSS (Mw 40,000) was obtained from TdB consultancy, DMEM, PBS and
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methanol was purchased from Thermo Fisher Scientific Inc., NH4Cl and Triton X-100 was
bought from Sigma, MPO and CXCR4 antibodies were purchased from Abcam.
2.2.2 Immunofluorescent staining
24 h prior to the experiment, CaCO2 cells were seeded in 8 well glass chambers
(Thermo Fisher Scientific Inc.) at 200,000 cells/ well in 500 µl media overnight. The cells
were then treated with 4% DSS in complete media for 24 h. After the treatment, the media
was removed and the cells were washed with ice PBS and fixed in 4 % PFA for 30 min.
The cells were washed with PBS between each step. The cells were then incubated with
50 µM NH4Cl for 10 min and washed. The cells were treated with chilled methanol for 10
min and washed before being treated with blocking buffer (0.01 % TritonX-100) for 1 h.
Post blocking, primary antibodies for CL1, CL2, CL3 and CL7 were added and the cells
were incubated on a shaker at 4°C overnight. On the following day, the cells were washed
and treated with the appropriate fluorescently labeled secondary antibody for 1 h. The
cells were then washed and then DAPI mounting media was added. The cells were
visualized using Zeiss 710 confocal laser scanning microscope.
2.2.3 Induction of DSS colitis
Male Balb/c mice (6 weeks old, 18-20g) were obtained from Charles River
Laboratories. All animal experiments were conducted according to the protocol approved
by the University of Nebraska Medical Center Institutional Animal Care and Use
Committee. Colonic inflammation was induced by substituting drinking water with 4 %
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DSS solution. Animals were weighed before starting the DSS. The onset and progress of
the disease was monitored by weighing the mice and presence of blood in the stool.
2.2.4 Induction of C. rodentium induced colitis
Male C57BL/6 mice (6 weeks old, 18-20g) were obtained from Charles River
Laboratories and used for all in vivo studies. All animal experiments were conducted
according to the protocol approved by the University of Nebraska Medical Center
Institutional Animal Care and Use Committee. C. rodentium was used to induce colitis in
mice as previously described [141]. Bacterial glycerol stock was streaked onto LB agar
plates and the bacterial colonies were grown overnight at 37°C. A single colony was
inoculated into 5 ml of 2% LB broth and incubated at 37°C, 280 rpm overnight to obtain a
saturated primary culture. On the day of the experiment (Day 0), 2 ml of the primary
culture was added into 300 ml of LB broth and the inoculum was placed on a shaker at
37°C at 280 rpm for 6 hours. Bacterial optical density was measured at 600 nm. Bacteria
were diluted with LB broth and delivered to mice (n=3) via oral gavage in a 100 µl volume
containing either 5 x 108 or 10 x 108 colony forming units (CFU). Healthy control group
(n=3) was orally administered 100 µl of LB broth.
2.2.5 Tissue harvesting and processing
On the day 7 for DSS model and Day 14 for the bacterial model, the mice were
sacrificed and the colons were harvested. For the DSS model, the fecal content was added
to a pre-weighed tube and the tubes were placed in an oven at 50°C for 48 h. The weight
of the dried feces was measured and the difference in the weights was used to calculate
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the water content. For animals from both the models, the colons were opened
longitudinally and excised into two parts along the length, which were stored accordingly
for determination of cytokine mRNA levels by RT-PCR and histological analysis.
2.2.6 RT-PCR
Colon samples were stored in RNAlaterTM (Thermo Fisher Scientific Inc.) at 4°C for
48 hours to allow sufficient time for tissue penetration followed by removal of excess
solution. The tissues were then stored at -80°C until further processing. Stored frozen
tissues were homogenized in TRIzolTM (Thermo Fisher Scientific Inc.) reagent using
TissueLyser II (Qiagen) and mRNA was isolated from the homogenized tissues according
to manufacturer’s protocol. The extracted mRNA was quantified using Nanodrop Onec
UV-Vis spectrophotometer (Thermo Fisher Scientific Inc.). The cDNA was synthesized
from the mRNA using High-Capacity cDNA Reverse Transcription Kit with RNase
Inhibitor per the manufacturer’s protocol (Thermo Fisher Scientific Inc.). A volume
corresponding to 1 µg of RNA as determined by UV spectrometer was used for cDNA
synthesis. Synthesized cDNA was stored at -20°C until further use. RT-PCR was carried
out using the synthesized cDNA from colon tissue samples to determine the levels of
mRNA of the target genes. Healthy and untreated colons were used as controls. cDNA
was mixed with 0.2 µM of primer pair of gene of interest and iTaqTM Universal SYBR®
Green Supermix (Biorad) into an optical reaction tube (Qiagen). The RT-PCR reaction was
carried out in Rotor-Gene Q 2plex thermal cycler (Qiagen) using the following cycle
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program: 95°C for 3 minutes; 40 cycles 60°C for 30 seconds. Results obtained from the RTPCR were analyzed by Ct method to determine the fold change in gene expression.
2.2.7 Histological studies
The part of the colon was rolled in a swiss roll fashion from distal to proximal end.
The rolls were fixed for 24 h in 4% paraformaldehyde, embedded in paraffin, sectioned
and stained with H&E. For other markers, the colon sections were stained with MPO (for
DSS treated colon tissue) and CXCR4 antibodies.
2.2.8 Spleen bacterial load
For the bacterial model, the spleens were harvested, weighed and stored on ice.
The spleens were homogenized in PBS and centrifuged at 15,000×g for 15 min at 4°C. The
supernatant was streaked onto LB agar plates and the plates were incubated at 37 °C for
24 h. After 24 h, the plates were visually inspected and the number of colonies was
counted.
2.2.9 Cytokine expression panel
Colitis was induced in male C57BL/6 mice using 5 x 108 CFU of C. rodentium as
described in the previous sections (n=15). Five mice were sacrificed at each time-point
(day 1, 10 and 14 after oral gavage of the C. rodentium). The colons were excised, cleaned,
and their weight and length recorded. The entire colon was frozen and stored at -80°C.
The colon was homogenized in 1.5 ml RIPA buffer using TissueLyserII (Qiagen) and the
homogenates centrifuged at 15,000×g for 15 min at 4°C. The supernatant was analyzed for
cytokine levels using ProcartaPlexTM Multiplex Immmunoassay (Invitrogen) following the
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manufacturer’s protocol. Briefly, magnetic beads coated with different cytokine
antibodies were added at the required dilution to 96-well plate. Supernatants from the
tissue homogenates and supplied fluorescent standards were added to the respective
wells. The cytokines were detected by adding a detection antibody followed by addition
of Streptavidin-PE. The beads were read on LuminexTM LX 200 Analyzer. The data
obtained were analyzed using ProcartaPlexTM Analyst software to obtain cytokine
concentrations.
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2.3 Results and Discussion
2.3.1 In vitro effect of DSS on tight junction proteins
We assessed the effect of DSS on claudins which are the tight junction proteins in
the colonic epithelium. The epithelial junctions in the colon represents one of the most
effective barriers in the body which regulates the transport of nutrients, electrolytes as
well as preventing luminal bacteria from infiltrating the colon tissue. Dysregulation of the
epithelial barrier leading to leakage of the luminal contents into the tissue results in the
immune response which causes inflammation. We tested the effect of DSS on tight
junction proteins in vitro in CaCO2 cell line which is an epithelial cell line. We assessed
the effect of DSS on expression of CL1, CL2, CL3 and CL7 in this cell line. We observed a
decrease in the expression of CL1 and CL7 which were located at the cellular junctions.
Post DSS treatment, these proteins appeared more punctate rather than at the tight
junctions. Similar pattern was observed for CL2 which are seen both at the junctions as
well as punctate. Post DSS treatment, CL2 showed a reduced expression overall. These
experiments showed that DSS had an effect on the tested tight junction proteins and
reduced their expression, thus affecting the integrity of the cell barrier.
We used two animal models for all the in vivo studies – DSS mouse model and C.
rodentium mouse model of colitis. Before utilizing the models in our studies, it was
important to confirm the suitability of the models to our experiments. It was essential to
characterize the model to make sure that they exhibited the histological as well as the
biochemical changes that commonly occur in human IBD. The following section will
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discuss the studies and the analysis carried out to make sure that the models were suited
to our studies.
2.3.2 DSS mouse model of colitis
One of the most commonly used animal models of colitis is a chemical injury
model using dextran sodium sulfate (DSS) [142]. The mechanism by which DSS induces
colitis is not entirely clear. However, it is postulated that the inflammation is likely due to
the damage caused to the epithelial monolayer allowing dissemination of luminal colonic
contents into the underlying tissue [143]. The DSS model is reproducible and the severity
of the colitis can be controlled by adjusting the dose and frequency of DSS administration.
One of the main advantages of the DSS-induced colitis is its histological similarity to
human colitis.
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Scheme 1. Timeline for the DSS model of colitis
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2.3.2.1 Macroscopic observations
The results of mice weight measurements are shown in Fig 3a. The DSS treated
group did not show any appreciable weight loss for the first five days of the experiment.
On the sixth day all the mice in the DSS group lost almost 10 % of their original body
weight. The weight loss continued the following date. On Day 7, the DSS group had lost
close to 20 % of their body weight. No weight loss was observed in the healthy control
group. Beginning day 3 most of the DSS treated mice began to show presence of blood in
the stool (not shown). On the day of the sacrifice, the feces were collected and the weight
before and after drying was determined (Fig. 3c). This allowed us to have an estimate of
the diarrhea. Diarrhea is a very common symptom of IBD and usually persists throughout
the course of the disease. We observed that the DSS group showed greater loss in fecal
weight post drying indicating the presence of more water in the feces. This showed that
the mice in the DSS group had diarrhea over the 7 days of DSS treatment. After sacrificing,
we measured the length and the weight of the colons. We observed that the length of the
DSS treated colon reduced significantly, however, the weight went up. As shown in Fig.
3b, the DSS group showed significantly higher weight by length ratio compared to the
healthy group. In human as well as murine IBD, the weight of the colon increases because
of the edema, immune cell infiltration and swelling which in turn also causes the colon to
reduce in length. These observations proved that the DSS treated mice were showing
symptoms as well as macroscopic parameters which are commonly observed in human
IBD.
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Figure 3. Macroscopic characteristics of DSS induced colitis. (a) Change in weight; (b)
Change in the weight by length ratio of the colon; (c) Loss in fecal weight on drying.
Results expressed as mean ± SD (n=5).
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2.3.2.2Histology and immune cell markers
In the H&E stained colon sections, we observed major histological changes in the
DSS treated group compared to the healthy controls (Fig. 4a). The colons of the DSS
treated mice exhibited inflammation-associated evidenced by crypt fall out, presence of
apoptotic cells and significant immune cell infiltrate. These changes correlated well with
the changes which occur in the histology in human IBD.
We also stained the tissue sections for MPO (Fig. 4b). MPO is an enzyme which is
specifically expressed by neutrophils which are the first immune cells in infiltrate the
inflamed tissue. As a result, MPO is commonly used as a marker for neutrophil
infiltration. We observed significantly higher MPO expression in the colons of the DSS
treated group. This showed that DSS-induced inflammation was resulting in higher
immune cell infiltration into the tissue compared to healthy control.
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Figure 4. Histological features of DSS induced colitis. (a) Representative images of H&E
stained control and DSS treated colon sections at various magnifications; (b) MPO stained
control and DSS treated colon sections 20X magnification (n=3.)
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2.3.2.3 CXCR4 expression
We also stained the colon sections for CXCR4 (Fig. 5). We observed higher
expression of CXCR4 in the damaged crypts which were a part of the epithelium. CXCR4
plays an important role in inflammation, however, its exact role in the pathophysiology
of IBD is unknown. CXCR4 is highly expressed on the peripheral T cells in patients with
IBD [144]. Normal intestinal epithelial cells have been reported to express CXCR4.
However, the expression of CXCR4 and CXCL12 is upregulated and more diffused in DSS
induced colitis with the epithelial cells as well as the infiltrating immune cells expressing
CXCR4 [145]. Our observations agree with previous studies. These studies point out that
CXCR4 is responsible in migration of immune cells into the inflamed colonic tissue.
Multiple reports have also pointed out the anti-inflammatory effect of CXCR4 blockade
either by antibodies or AMD3100 in human IBD as well as animal model of colitis [146].
Our findings confirm the presence of CXCR4 expression in DSS model of colitis as well as
draw confidence from reports that it can be a viable target to test our system discussed
further.
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Figure 5. CXCR4 expression in DSS induced colitis. (a) Representative images of control
and DSS treated colon sections stained for CXCR4 at 20X magnification (n=3).
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2.3.3 C. rodentium model of colitis
As a second model of colitis, we decided to study and see whether C. rodentium
induced colitis was suited for out studies. DSS model is a chemical induced injury model
which gives a robust and replicable colonic inflammation in mice. However, the most
characterized aspect of IBD pathophysiology involves immune response to bacterial
infiltration from the lumen into the colonic mucosa. The DSS model fails to capture that
aspect of the disease. C. rodentium is bacteria which is very similar to E. coli which is the
major bacteria involved in the development of human IBD. It attaches to the apical side of
the colon epithelium and invades the colon wall, thus eliciting an immune response [141].
As a result, C. rodentium colitis mimics the immune response to luminal bacteria which is
one of the explanations in IBD pathogenesis, thus making it a biorelevant model. Unlike
DSS which requires continuous administration at least for 7 days, C. rodentium model only
necessitates single dose of bacteria which places relatively less stress on the animals. Other
than the mentioned advantages, C. rodentium induced colitis also shows less interference
with RT-PCR as well as testing of delivery systems which are commonly observed with
DSS induced colitis [147]. We did a few characterization experiments to assess the
suitability of this model to our studies.

49

Scheme 2. Timeline for C. rodentium model of colitis

50

2.3.3.1 Macroscopic observations
Over the 14 days of the induction, we weighed the mice every day. As opposed to
the DSS model, weight reduction as well as presence of blood in stool are not significant
characteristics of this model. Mice from both the groups which received bacteria did not
exhibit any significant weight loss (~5% weight loss) (Fig. 6a).
Post sacrifice, we observed significant reduction in colon length for the mice which
received the bacteria. In contrast, the weight of the colons from the bacteria group was
significantly higher compared to healthy control (Fig. 6b). The increase in colon weight
was the indication of inflammation in edema induced by C. rodentium. The increase in the
colon weight was found to be bacterial dose dependent (Fig. 6c).
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Figure 6. Macroscopic characteristics of C. rodentium induced colitis. (a) Change in weight;
(b) Representative images of the colon; (c) Colon weight. Results expressed as mean ± SD
(n=3).
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2.3.3.2 Weight change and bacterial load in the spleen
We harvested the spleen and carried out further analysis. We observed a
significant and dose dependent increase in the weight of the spleen (Fig. 7b). After
infiltration into the colonic mucosa, the bacteria usually translocate to spleen which in the
main organ involved in clearing of the infection. This results in the enlargement and
subsequent increase in spleen weight (Fig 7a). We also measured the bacterial spleen load
by plating the spleen homogenate on agar plates and counting the colonies that grew
overnight (Fig. 7c). The healthy control spleens did not show any colonies after 24 h.
However, spleens from both the bacteria treated groups showed bacterial growth
confirming the translocation of the bacteria from the colon to the spleen.
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Figure 7. Changes in the spleen of C. rodentium infected mice. (a) Representative images
of the spleens; (b) Weight of the spleen; (c) Bacterial load in the spleen. Results expressed
as mean ± SD (n=3).
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2.3.3.3 Histology
Histologically, colons of the infected mice exhibited inflammation-associated
epithelial changes evidenced by crypt elongation, crypt fall out, presence of apoptotic
cells, and significant inflammatory cell infiltration (Fig. 8). Distal colon showed more
pronounced changes than the proximal colon, which was consistent with previous
findings suggesting that C. rodentium preferentially colonizes the distal colon. The
observed parameters correlate well with the inflammatory changes, which occur during
the development of human IBD.
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Figure 8. Histological changes in the colons of C. rodentium infected mice. Representative
images of H&E stained colon sections.
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2.3.3.4 Cytokine expression
It involves an erratic immune response to the gut microbiota and luminal contents
which leak into the tissue when the epithelial barrier is broken. As a result, upregulation
of pro-inflammatory cytokines is a hallmark of IBD. Cytokine dysregulation is a common
aspect across all the animal models of IBD. The network of cytokines involved in IBD is
which a variety of chemokines and growth factors are involved. However, most of the
studies are restricted to individual cytokines. Many studies indicate the diagnostic value
of cytokine profiling in IBD to design cytokine-based therapies [148]. As a result, we
carried out a time dependent profiling analysis of local colonic cytokine levels in C.
rodentium infected mice and observed many changes in the colon cytokine levels. Many
cytokines of the IL family play a role in many autoimmune disorders [149]. We observed
a time dependent increase in the colon levels of IL-1β, IL-6, IL-13 (Fig. 9). The main source
of IL-1β in IBD are the monocyte and macrophages which release IL-1β into the colonic
mucosa [150]. IL-6 was the cytokine which showed highest upregulation in colon levels.
IL-6 signaling plays an important role in IBD pathogenesis via activation of STAT3 and
has been commonly observed to be upregulated in IBD patients [151]. Not only
mononuclear cells but also intestinal epithelial cells have been reported to be involved in
producing IL-6 in lamia propria [152]. IL-13 has been reported to be an important cytokine
in UC which is traditionally considered as a Th2 mediated disorder [153]. IL-13 mRNA
levels are increased not only in UC affected mucosa, but also in lamia propria cells from
patients cultured ex vivo [154]. We also observed a time dependent increase in the levels
of TNFα. TNFα is heavily involved in the pathogenesis of IBD [155]. It has been reported
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to exert pleiotropic effects as well as increase the production of IL-1β, IL-6 [156, 157]. The
levels of TNFα have been shown to correlate with the disease activity index of IBD [157].
As a result, the most successful therapy for IBD are the TNFα antibodies [158]. The
increase in the levels of all the cytokines results in over production of chemokines which
involve majority of MCPs, MIPs and MMPs. These molecules play a major role in the
recruitment and the migration of circulating immune cells [159]. We observed an
upregulation in the levels of MCP-1, MCP-3, MIP-α, MIP-β in the colons of the infected
mice (Fig. 10). Overall, the profiling of the cytokines in model revealed a time dependent
increase in the levels over the 14 days of the model. The upregulation in these cytokines
correlated with the histological changes we observed in this model.
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Figure 9. Changes in cytokine levels in C. rodentium infected mice. Colon cytokine levels
were measured using Luminex cytokine panel (a) IL-1β; (b) IL-6; (c) IL-13; (d) TNFα; (e)
MCP-4; (f) MCP-3; (g) MIP-α; (h) MIP-β. Results expressed as concentration in pg/ml
(n=5).
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Figure 10. Changes in cytokine levels in C. rodentium infected mice. Colon cytokine levels
were measured using Luminex cytokine panel (a) MCP-4; (b) MCP-3; (c) MIP-α; (d) MIPβ. Results expressed as concentration in pg/ml (n=5).
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2.3.3.5 CXCR4 expression
We also assessed the mRNA levels of CXCR4 in the colon of C. rodentium infected
mice (Fig. 11). We observed that CXCR4 mRNA levels were upregulated two-fold right
from Day 2 post infection. Maximum fold increase in mRNA levels compared to healthy
control was observed on Day 10, almost 5-fold. CCR4 mRNA levels decreased slightly on
Day 14 compared to Day 10. A four-fold increase in CXCR4 mRNA levels was observed
on Day 14 compared to healthy control.

CXCR4 mRNA fold change
(relative to control animals)
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Figure 11. Changes in CXCR4 expression in C. rodentium infected mice. Colon CXCR4
mRNA levels over the course of the model measured using RT-PCR. Results are expressed
as fold change in mRNA levels relative to healthy controls (n=3).
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2.4 Conclusion
Our characterization of revealed the both the models gave a robust inflammation
which was mainly localized in the colon. Both the models showed macroscopic
characteristics, histological characteristics and the biochemical parameters similar to
changes which occur in human IBD. All these factors can be used to compare the efficacy
of our treatments. In conclusion, both the models are suitable for our planned studies.
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Chapter 3: Polymeric chloroquine as an oral therapeutic for treatment of IBD
3.1 Introduction
Polymers have been as therapies since a long time. PDC involve conjugating
macromolecular polymers with drugs and have been applied as a promising drug
delivery platform. In the last few years, the use of PDC in novel therapeutic applications
is increasing. The first PDC reported conjugated mescaline with poly (vinyl pyrrolidine)
in 1955. Following that, many PDCs have been synthesized and reported. Most common
aim behind synthesizing a PDC is to change the characteristics of the free drug. Few
common advantages a PDC may offer over a free drug involve increased water solubility,
control of the release pattern of the drug, protection of the drug against degradation under
physiological conditions, improved bioavailability in the target tissue. For a considerable
time, only the physical properties of the drug were considered in designing a PDC. As a
result, not all drugs were appropriate to be modified as PDCs. However, eventually the
consideration of the route of administration became important as it has an impact on the
accessibility of the drugs to their target site. With oral route of administration intended
for drug delivery to the colon, it is important that the drug remains conjugated when
during the transit as it encounters various pH and enzymatic conditions. There are
numerous reports of PDCs synthesized with various goals have been synthesized for oral
administration. Budesonide was conjugated with dextran for improving its aqueous
solubility as well as reduce premature release in the upper GIT. A colon specific release
of the drug obtained by degradation of the dextran backbone by dextranase, an enzyme
present specifically in the colon. Another example was conjugation of Dexamethasone to
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pDMAEMA to improve its mucoadhesive properties in the GIT and provide an enhanced
anti-inflammatory effect. A commercial example of PDC is NKTR-118, a PEGylated form
of naloxol which is currently under Phase III trials as an oral tablet for opioid-induced
bowel disorders.
Chloroquine (CQ) is commonly used to prevent and treat malaria. In recent years,
CQ has also found growing anti-inflammatory application in the treatment of
autoimmune disorders like rheumatoid arthritis and lupus erythematosus [160]. Several
reports indicate the promise of CQ in treating IBD [161]. However, the long-term use of
CQ can result in severe ocular side effects including blurred vision and retinopathy [162].
We have previously synthesized a polymeric form of CQ (pCQ), which showed
unexpected ability to safely inhibit cell migration. The epithelial tight junctions in the
colon is one of the most regulated barriers in the body. It promotes the transport of
nutrients and small molecules from the lumen into the systemic circulation, but
macromolecules are virtually prevented from passing through. With pCQ being a
macromolecule, we hypothesized that restricting it to the colon and minimizing systemic
absorption could be a promising strategy to enhance its local anti-inflammatory effect in
IBD (Scheme 3). We hypothesize that pCQ will have enhanced anti-inflammatory activity
in IBD. In our current study, we analyzed the oral pharmacokinetics and evaluated
therapeutic efficacy of pCQ using a widely used mouse model of IBD induced by oral
administration of C. rodentium.
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Scheme 3. Proposed mechanism of pCQ
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3.2 Materials and methods
3.2.1 Materials. Hydroxychloroquine (HCQ) sulfate (98%), triethylamine, DMSO-d6
(99.8%) and chloroform-d (99.8%) were obtained from Acros Organics (Fisher Scientific).
Methanol, acetonitrile (HPLC grade) were purchased from Fisher Scientific. pCQ (Fig. 1)
with 16.7 mol % of CQ and weight average molecular weight 60 kDa was synthesized and
characterized as previously reported [163].
3.2.2 Pharmacokinetics and biodistribution. The pharmacokinetics and biodistribution
of single dose pCQ was evaluated in a mouse model of IBD. Colitis was induced using C.
rodentium as described above and on day 14, the mice were given single dose of HCQ or
pCQ in 200 µl of deionized water via oral gavage equivalent to 30 mg/kg HCQ. Blood was
collected from the submandibular vein at 0.5, 1, 2, 4, 8, and 24 h post-administration. The
animals were sacrificed and organs harvested at 0.5, 2, 8, and 24 h post-administration
and stored at -80°C until further use. The mice were randomized to selected sampling
times so that three blood samples and one terminal tissue collection were obtained from
each. We have previously reported the single dose intra venous pharmacokinetics of HCQ
in mice [164].
Blood, tissue and fecal samples were processed by two methods to determine free HCQ
and total HCQ. For the first method, HCQ was isolated by a simple extraction from the
organs as previously described [164]. The second method utilized base hydrolysis to
release HCQ covalently bound to pCQ and subsequent HCQ extraction using solid phase
extraction (SPE). Tissues and feces were homogenized in water prior to loading to the SPE
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cartridge. The calibration and quality control samples were separately prepared for HCQ
and pCQ by spiking 10 µl of appropriate calibration stock of HCQ and pCQ, in 100 µl of
blank biomatrix, and 10 µl of internal standard solution (1.0 µg/ml) was added. For the
study, 25 µl of blood and 100 µl of tissue homogenate were used. 400 µl of 1 M NaOH,
600 µl water and 100 µl methanol were added and the samples were incubated at 50 ºC
for 1 h to hydrolyze HCQ from the pCQ. Subsequently, 400 µl 2% formic acid was added
and the samples were vortexed for 30 s and centrifuged at 1300 x g for 10 min. The SPE
was carried out using Oasis HLB 3cc, 60 mg extraction Cartridge (Waters). Cartridges
were pre-conditioned with 1 ml acetonitrile followed by 1 ml water. Samples were loaded
to the cartridges and washed with 2 ml of aqueous 15 % methanol and dried at high
vacuum for 15 min. Analytes were eluted with 2 ml of acetonitrile. The eluents were
collected in glass tubes and dried under nitrogen in water bath at 50C. The dry residues
were reconstituted in 400 µl 0.1% formic acid:methanol mixture (60:40) and centrifuged at
13000 x g and 10 µl supernatant was injected into the HPLC. The LC-MS/MS conditions
used were according to our previous report [164]. The assay was linear over the range of
1 to 2000 ng/mL.
The pharmacokinetic parameters of HCQ and pCQ in blood and tissues were calculated
using non-compartmental analysis with Phoenix WinNonlin 6.3 (Pharsight Corporation).
The maximum concentration (Cmax) and time to Cmax (Tmax) were obtained from visual
inspection of the concentration-time plot. The area under the curve (AUC0-) was
estimated using the linear trapezoidal method from 0-tlast and extrapolation from tlast to
infinity based on the observed concentration at the last time point divided by the terminal
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elimination rate constant (). The elimination half-life (t1/2) was calculated as 0.693/k.
Apparent clearance (Cl/F) and the apparent volume of distribution of the elimination
phase (Vd/F) were calculated as dose/AUC0- and dose/k*AUC0-, respectively. The mean
residence time (MRT) was calculated as AUMC0-/ AUC0-. Mean tissue concentrations
were calculated and expressed as ng/g tissues. The absolute bioavailability was calculated
as:

3.2.3 Therapeutic efficacy. Colitis was induced as stated above and mice were randomly
assigned to healthy, HCQ, and pCQ treatment groups (n=5) and untreated group (n=8).
Starting day 1, the mice received oral gavage of either HCQ or pCQ every other day (30
mg/kg HCQ equivalent in 200 µl sterile deionized water). Untreated controls were
administered 200 µl sterile deionized water. On day 14, the mice were sacrificed and the
colons were harvested. The colon was opened longitudinally, cleaned of fecal matter, and
excised into two parts along the length, which were stored accordingly for determination
of cytokine mRNA levels by RT-PCR and histological analysis.
3.2.4 Real-time PCR (RT-PCR). Colon samples from the therapeutic study were stored in
RNAlaterTM (Thermo Fisher Scientific Inc.) at 4°C for 48 hours to allow sufficient time for
tissue penetration followed by removal of excess solution. The tissues were then stored at
-80°C until further processing. Stored frozen tissues were homogenized in TRIzolTM
(Thermo Fisher Scientific Inc.) reagent using TissueLyser II (Qiagen) and mRNA was
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isolated from the homogenized tissues according to manufacturer’s protocol. The
extracted mRNA was quantified using Nanodrop One c UV-Vis spectrophotometer
(Thermo Fisher Scientific Inc.). The cDNA was synthesized from the mRNA using HighCapacity cDNA Reverse Transcription Kit with RNase Inhibitor per the manufacturer’s
protocol (Thermo Fisher Scientific Inc.). A volume corresponding to 1 µg of RNA as
determined by UV spectrometer was used for cDNA synthesis. Synthesized cDNA was
stored at -20°C until further use. RT-PCR was carried out using the synthesized cDNA
from colon tissue samples to determine the levels of mRNA of the target genes. Healthy
and untreated colons were used as controls. cDNA was mixed with 0.2 µM of primer pair
of gene of interest (Table 1) and iTaqTM Universal SYBR® Green Supermix (Biorad) into an
optical reaction tube (Qiagen). The RT-PCR reaction was carried out in Rotor-Gene Q
2plex thermal cycler (Qiagen) using the following cycle program: 95°C for 3 minutes; 40
cycles 60°C for 30 seconds. Results obtained from the RT-PCR were analyzed by Ct
method to determine the fold change in gene expression.
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Table 2. Primer sequences for RT-PCR
mRNA targets
TNF-α
IL-6
IL-1β
IL-2

F
R
F
R
F
R
F
R

Primer sequence (5’-3’)
CATGAGCACAGAAAGCATGATC
CCTTCTCCAGCTGGAAGACT
ATGGATGCTACCAACTGGAT
TGAAGGACTCTGGCTTTGTCT
CAACCAACAAGTGATATTCTCCATG
GATCCACACTCTCCAGCTGCA
TGAGCAGGATGGAGAATTACAGG
GTCCAAGTTCATCTTCTAGGCAC
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3.2.5 Histological evaluation. The longitudinally opened colons were rolled into a Swiss
roll from distal to proximal end. The rolls were fixed for 24 h in 4% paraformaldehyde,
embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E). The
stained sections were evaluated by a pathologist without the knowledge of the identity of
the samples using a light microscope. Histopathological scores were assigned based on
criteria as previously described [165]. Scoring was performed based on severity of
epithelial injury (graded 0-3, from absent to mild including superficial epithelial injury,
moderate including focal erosions, and severe including multifocal erosions), the extent
of inflammatory cell infiltrate (graded 0-3, from absent to transmural), and goblet cell
depletion (0-1). For each tissue, a numerical score was assigned in a blinded manner to
prevent bias. Scores from each tissue section group were averaged to obtain a mean
histopathological score. Crypt heights were measured using ImageJ software, with 10
measurements taken in distal colons of each mouse. Only well-oriented and intact crypts
were measured. Tissue sections were stained for cleaved caspase 3 (CC3) and macrophage
infiltration (CD68). CC3 positive cells in the entire colon roll were counted at 20x
magnification. Results were expressed as mean CC3 positive cells per entire colon roll.
CD68 positive cells were counted in five randomly chosen areas in the colon roll at high
power field (HPF). Results were expressed as mean of CD68 positive cells per HPF.
Statistics. Mann-Whitney test was used for statistical analysis of mean differences
between treatment groups for biodistribution studies. One-way ANOVA followed by
Tukey multiple comparison test was used for statistical analysis of mean differences
among multiple groups. A value of p < 0.05 was considered statistically significant. All
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statistical analysis was performed using Graphpad Prism v5 (ns = not significant, * = p ≤
0.05, ** = p ≤ 0.01, *** = p ≤ 0.001)
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3.3 Results and discussion
The main hypothesis of this study was that the macromolecular nature of pCQ will
significantly restrict oral bioavailability of chloroquine and thus allow us to test how local
colon effects contribute to the overall anti-inflammatory activity of HCQ. Based on our
prior studies, we further hypothesized that pCQ will act as a polymeric drug with
pronounced ability to inhibit inflammatory cell infiltration in the colon. We have
synthesized pCQ by copolymerization of N-(2-hydroxypropyl)methacrylamide (HPMA)
with methacryloylated HCQ as reported in our previous studies (Fig. 12) [166].
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Figure 12. Structures of HCQ, pCQ and main HCQ metabolites
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3.3.1 Pharmacokinetics
pCQ contains HCQ attached by a potentially hydrolyzable ester linker and it was
thus important to be able to distinguish between polymer-conjugated HCQ and free HCQ
released from pCQ (Fig. 12). We achieved this goal by using two LC-MS/MS analytical
methods. First, we quantified HCQ using a simple extraction from blood and tissues to
determine the amount of HCQ that was released from pCQ by hydrolysis in the GI tract,
blood, or liver. In the second method, we included an alkaline hydrolysis step that was
optimized to fully hydrolyze the ester linker between HCQ and the polymer, thus
providing us with the information on the total (polymer bound + hydrolyzed) HCQ. The
difference in the HCQ amount obtained from the two methods was used to calculate the
percent of HCQ in the tissues that remained bound to the polymer. We have found that
the HCQ amount quantified by both methods was similar in blood and tissues from
animals treated with HCQ alone.
The blood concentration vs. time profile for the HCQ and pCQ after oral
administration is shown in Fig. 13. The PK parameters of pCQ were determined from the
total HCQ content in the blood and thus represent a combined PK of polymer-bound and
hydrolyzed HCQ (Table 3). The drug reached a maximum concentration in blood (Cmax)
of 2342.6 ± 46.3 and 12.2 ± 1.7 ng/mL for HCQ and pCQ treatment, respectively. The value
of area under curve (AUC0-∞) were determined as 28182.4 ± 1475.8 and 231.3 ± 48.8
hr×ng/mL for HCQ and pCQ treatment, respectively. In comparison to HCQ, the pCQ
formulation exhibited a significant reduction of Cmax (~192 fold) and AUC0–∞ (~122 fold)
indicating that modifying HCQ into pCQ dramatically reduced its absorption. The
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absolute bioavailability (oral to IV), was found to be 0.4% for pCQ compared to 80% for
HCQ indicating that the pCQ formulation substantially reduced HCQ bioavailability and
maintained drug in the gastrointestinal tract. One pharmacokinetic disadvantage of
chloroquine and its metabolites is their exceptionally long residence time in the blood
leading to severe side effects. In pCQ treatment group, HCQ levels were substantially
lower in the systemic circulation, suggesting that prolonged exposure to HCQ and
metabolites will not be a major systemic toxicant. This is an important finding for a small
molecule drug like chloroquine which has high systemic bioavailability resulting in high
non-specific tissue exposure. Reduction in systemic absorption and bioavailability is
important for local therapy and reduction of systemic toxicities and our pCQ formulation
resulted in very different blood PK profile compared to HCQ.
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Figure 13. Blood concentration vs. time profile. Mice with C. rodentium induced colitis
were orally administered with HCQ and pCQ equivalent to 30 mg/kg CQ dose,
respectively. Results are expressed as HCQ blood concentration ± SD.

Table 3. Non-compartmental blood pharmacokinetic analysis in colitis mice
Pharmacokinetic
parameter

HCQ

pCQ

Cmax (ng/ml)

2,343 ± 46

12.2 ± 1.7

t1/2 (h)

5.6 ± 1.9

11.7 ± 3.6

tmax (h)

3.3 ± 1.2

4.7 ± 3.1

AUC0-last (h×ng/ml)

26,446 ± 507

161 ± 8

AUC0- ∞ (h×ng/ml)

28,182 ± 1476

231 ± 49

Cl/F (L/h/kg)

1.1 ± 0.1

134 ± 27

MRT (h)

6.8 ± 0.6

9.9 ± 0.7
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3.3.2 Colon and liver distribution
There have been numerous reports indicating that conjugating small molecule
drugs with polymers can change their PK and pre-dispose them to preferential
accumulation in specific tissues. We next analyzed how the differences in blood PK affect
relative distribution of pCQ and HCQ to the colon and liver following oral administration
in the C. rodentium colitis model. The colon and liver PK and distribution results are shown
in Table 3 and Fig. 14. HCQ and pCQ reached a Cmax of HCQ in colon of 10,304 ± 746 and
7,121 ± 2,984, respectively. The colon AUC0–∞was 208,917 ± 55,806 for HCQ and 94,515 ±
35,363 hr×ng/mL for pCQ treatment. HCQ appeared to show higher colon concentrations
than pCQ probably due to faster transit time but the difference did not reach statistical
significance. Both HCQ and pCQ showed increasing accumulation in the colon from the
time of administration until at least 8 h, with subsequent decline by 24 h (Fig. 14). Both
pCQ and HCQ showed similar colon PK behavior. The Tmax for HCQ and pCQ occurred
at 8 h. However, major differences were observed in the hepatic PK parameters of pCQ
and HCQ. As expected from the very low bioavailability, pCQ had much lower hepatic
accumulation than HCQ with the liver Cmax for pCQ 58-times lower than the HCQ Cmax
and ~110-times lower AUC0–last compared to HCQ.

It was noteworthy, that pCQ

concentrations in the liver declined from the first measured time point and were at all
times lower than the liver levels of HCQ. These PK differences contributed to the
preferential localization of pCQ in the colon as suggested by the calculated colon-to-liver
ratios in Fig. 14. The pCQ colon:liver ratio was higher at all measure time points compared
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to HCQ treatment. Fecal pCQ concentrations were higher than HCQ levels (data not
shown). These observations reinforce the applicability of pCQ as a local colonic treatment.
Having established the local colon accumulation of pCQ, we then focused on the
analysis of pCQ hydrolysis in the GI tract and the extent of release of free HCQ. We have
analyzed the content of polymer-bound HCQ and the extent of pCQ hydrolysis using the
two different sample preparation methods described above. As shown in Fig. 15, we have
found that the vast majority (~97%) of the HCQ was polymer-bound until at least 24 h
post-administration. The released (i.e. free) HCQ levels in the colon decreased, whereas
the polymer-bound HCQ levels increased over time. While the released HCQ
concentrations were highest in the colon at 1.5 h, the polymer-bound HCQ achieved
maximum concentrations at 8 h. Calculating the hydrolyzed fraction at 8 h, only 1.2% of
free HCQ was present in the colon tissue. This indicated that the hydrolyzed HCQ was
being systemically absorbed while the polymer-bound HCQ had a higher transit time to
localize in the colon before clearance at 24 h. Estimate of the colon AUC0-last showed about
37-fold difference between the polymer-bound HCQ and HCQ hydrolyzed from pCQ,
suggesting that most of the therapeutic effects described below result from the activity of
pCQ and not released HCQ.
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Figure 14. Biodistribution of HCQ and pCQ. Animals were sacrificed at pre-determined
timepoints and tissues were harvested and homogenized. HCQ levels were measured in
liver and colon. Results are expressed as concentration of HCQ in tissues ± SD.

Table 4. Liver and colon pharmacokinetics in colitis mice.
Liver

Colon

Pharmacokinetic
parameter

HCQ

pCQ

HCQ

pCQ

Cmax (ng/ml)

12,807±3703

220.2±102.7

10,304 ± 746

7,121 ± 2,984

tmax (h)

2.0±0.0

0.5±0.0

8.0±0.0

8.0±0.0

AUC0-last
(h×ng/ml)

167,944 ± 19,302

1,547 ± 100

166,377 ± 14,873

93,088 ± 34,403

AUC0- ∞ (h×ng/ml)

175,852 ± 18,362

1,659 ± 78

208,917 ± 55,806

94,515 ± 35,363
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Figure 15. GI hydrolysis of pCQ. HCQ extracted with (polymer-bound) and
without base hydrolysis (released) was measured in colon. Results are expressed
as concentration of HCQ in colon ± SD.
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3.3.3 HCQ and pCQ metabolism
To address tissue accumulation and subsequent metabolism of HCQ and pCQ, we
measured the concentrations of HCQ metabolites in colon and liver at serial time points
following oral administration. HCQ is metabolized in the liver by dealkylation into three
major metabolites (Fig. 12): desethylchloroquine (DCQ), bisdesethylchloroquine (BDCQ)
and desethylhydroxychloroquine (DHCQ) [167]. It was previously shown that DCQ has
similar antimalarial activity as HCQ. All the N-dealkylated metabolites have been
implicated in heart failure and retinopathy, with BDCQ being more cardiotoxic than HCQ
[168]. Importantly for chronic use in IBD, HCQ and its metabolites have extremely long
biological half-lives and thus their monitoring is important.
As expected, pCQ significantly decreased the extent and rate of HCQ metabolism
due to the covalent bond formed between the polymer and the hydroxyl in HCQ. The
metabolite concentration results in liver and colon are shown in Fig. 16. In the liver (Fig.
16a), which is the main organ for HCQ metabolism, both DCQ and BDCQ concentrations
were 10-100-fold higher in the HCQ treated group as compared to the pCQ group. Both
DCQ and BDCQ liver concentrations peaked at 8 h. DHCQ liver levels were undetectable
in the pCQ group. Analysis of blood metabolite concentrations revealed similar trend as
most metabolites were either undetectable or significantly lower in the pCQ group as a
result of the very low bioavailability (data not shown).
Data in Fig. 16b suggest that HCQ metabolism occurs in the colon. In agreement
with the liver metabolism findings, we observed that metabolite concentrations were
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about 10-100-fold lower in the pCQ group than in the HCQ group. Calculating the percent
of metabolites in colon at Cmax (8 h), we observed that pCQ was metabolized to a lower
extent than HCQ. While the major metabolite DCQ accounted for 16.5% in the HCQ
group, only 4% of pCQ was metabolized to DCQ in the colon. BDCQ (4% of HCQ vs. 0.4%
of pCQ) and DHCQ (8% of HCQ vs. 1% of pCQ) showed similar differences. This finding,
coupled with the observation of elevated fecal pCQ concentrations, further support pCQ
localization in the colon as opposed to systemic absorption. The covalent conjugation of
HCQ in pCQ not only reduced its oral absorption due to its macromolecular nature but it
also decreased accessibility to metabolic enzymes, thus preventing generation of toxic
HCQ metabolites. Such a low systemic exposure to HCQ and its metabolites may result
in reduction of adverse systemic side effects commonly observed with HCQ.
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Figure 16. Metabolite levels of HCQ and pCQ in (a) liver and (b) colon. Tissue
homogenates were analyzed for metabolites. Data are represented as mean metabolite
concentration in ng/g of tissue.
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3.3.4 Therapeutic efficacy
The local colon accumulation, limited systemic exposure, and low liver
distribution of pCQ provided strong rationale for the testing of its anti-inflammatory
activity in colitis. We conducted a therapeutic efficacy study designed to assess whether
restricting the distribution of pCQ to the GI tract preserves the activity of HCQ. The mice
with colitis were treated (every other day) with oral gavage of pCQ and HCQ. Histological
changes in the colon were examined following animal sacrifice on day 14. As shown in
Fig. 17, untreated animals showed superficial epithelial damage, marked reduction in the
goblet cell population, mucin depletion, inflammatory cell infiltration and crypt
hyperplasia [141]. Treatment with both, pCQ and HCQ, reduced the colon inflammation
and eased the epithelial injury (Fig. 17a). Statistically significant reduction of the
histological damage score was observed in animals treated with pCQ (Fig. 17c). Both
treatments significantly reduced the colon crypt length when compared with the
untreated group (Fig. 17b). Our findings support previous reports showing the efficacy of
chloroquine in DSS-induced model of colitis and human patients [157, 161, 169].
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Figure 17. Effect of HCQ and pCQ on C.rodentium-associated colonic inflammation. Mice
with C.rodentium induced colitis were orally administered with 7 doses at 30mg/kg CQ
dose over 14 days. (a) Representative images of H&E stained colon tissue slides; (b) colon
crypt length; (c) histopathological scores. Data are represented as mean ± SD.
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To assess the immunohistochemical changes that occur during inflammation, we
determined the effect of pCQ treatment on the expression of two markers (CD68, CC3)
that are commonly measured in reported in vivo IBD studies. CD68 is a transmembrane
glycoprotein specifically expressed by monocytes and macrophages. CD68 plays an
important role in macrophage homing to tissues and is used to study macrophage
infiltration in the inflamed colon. Colon sections from patients with active IBD have
significantly higher macrophage infiltration than healthy subjects [170]. We observed
elevated infiltration of CD68+ macrophages in the colons of untreated mice with colitis
(Fig. 18a). Treatment with pCQ and HCQ showed statistically significant reduction in the
macrophage infiltration, with pCQ outperforming HCQ (Fig. 18b). CD68+ macrophages
have different roles in UC and CD, but they massively infiltrate throughout the inflamed
colon [171] and targeting CD68 to reduce macrophage infiltration is a potential
therapeutic strategy in IBD [172]. Based on our prior work which showed a broad ability
of pCQ to inhibit migration and invasion of cells, we propose that reduction of
macrophage infiltration could be a possible mechanism by which pCQ is exerting its antiinflammatory activity. We next evaluated apoptosis as a marker for epithelial cell injury.
CC3 immunostaining was used assess the apoptotic cells in the colon epithelium and we
found that pCQ treatment showed statistically significant reduction in the number of
apoptotic epithelial cells when compared with the untreated group (Fig. 18d). This
observation combined with the decrease in the crypt length demonstrates the
amelioration of epithelial cell injury by pCQ.
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Figure 18. Effect of HCQ and pCQ on colonic macrophage infiltration and epithelial cell
apoptosis. (a) Representative images of CD68 stained colon tissue slides; (b) quantitative
results of CCD68 positive cells. Data are represented as mean CD68 positive cells per HPF
± SD. (c) Representative images of CC3 stained colon tissue slides; (d) quantitative results
of CC3 positive cells. Data are represented as mean CC3 positive cells/ colon section ± SD.
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3.3.5 Mechanism of action
Following histological evaluation, we sought to explore possible mechanisms for
the anti-inflammatory activity of pCQ. Upregulation of pro-inflammatory cytokines is a
hallmark of IBD and lowering local levels of cytokines has been shown to reduce colon
inflammation. To investigate how pCQ treatment changes the cytokine expression profile,
we measured the mRNA levels of selected pro-inflammatory cytokines in the colons after
oral administration of seven doses of pCQ over 14 days. Although inhibition of TNFα is
a well-established approach in the treatment of IBD and TNFα expression was 5-times
higher in the untreated group, we observed no significant reduction in the colon TNFα
expression after treatment with pCQ (Fig. 19a). We then measured expression levels of IL6, IL-1β and IL-2 in the colon. Our initial studies indicated that IL-6 was highly
upregulated in the C. rodentium model. Here, we have observed statistically significant
reduction of IL-6 expression by both pCQ and HCQ (Fig. 19b). We have observed similar
effect of pCQ and HCQ treatments on the expression of IL-1β (Fig. 19c).
In contrast to IL-6 and IL1β, both treatments resulted in upregulated IL-2
expression (Fig. 19d). Statistically significant difference was observed between IL-2 levels
in untreated control and pCQ group. IL-2 knockout mice are an often-used animal model
of IBD and there has been a reported clinical trial which investigated subcutaneously
administered IL-2 as a way of enhancing regulatory T cells in IBD patients to reduce
inflammation [173]. Based on these findings, upregulation of IL-2 may represent an
interesting direction in the mechanistic studies of pCQ anti-inflammatory activity.
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IL-6 has been the target of many mechanistic as well as clinical and preclinical studies
[174]. The IL-6 downstream pathways promote immune response by increasing the CD4+
T-cell migration into the inflamed colon, which consequently increases the migration of
other immune cells to the inflamed areas [175]. Accumulated evidence suggests that
activation of IL-6 is an important inflammatory event in the development of IBD. Hence,
inhibiting IL-6 signaling pathways represents a possible mechanism for the observed antiinflammatory activity of pCQ [176]. Overall, our observations pointed out that the
therapeutic activity of pCQ seemed to be an effect of restoring the colonic immune
imbalance that occurs in IBD.
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Figure 19. Effect of HCQ and pCQ on murine colonic cytokine levels. Fold change in
colonic mRNA expression relative to healthy control (a) TNF-α; (b) IL-6;(c) IL-1β; (d) IL2. Data are represented as mean ± SD.

92

3.4 Conclusions
This is the first report on the local anti-inflammatory effect of non-absorbable
polymeric form of HCQ. We have demonstrated promising therapeutic efficacy of pCQ
in murine model of colitis induced by infection with C. rodentium. Unlike epithelial injury
models of IBD, this model captures the immunological and microbiological aspects of IBD,
making it more relevant to human disease. Despite comparable colon accumulation as
HCQ, pCQ showed significant reduction in colon inflammation. Further improvement of
pCQ accumulation in the inflamed colon is likely to enhance the effect. We identified
several putative mechanisms of action for pCQ as an anti-inflammatory agent. Imbalance
of the immune system plays a major role in IBD and our investigation suggests that pCQ
may restore the homeostasis between the pro-inflammatory and anti-inflammatory
aspects of the immune system in the colon. The exact mechanism of how pCQ exerts its
therapeutic activity is beyond the scope of this report and will be a topic for future
investigations. Our findings are important for the development of safer local IBD
therapies.
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Chapter 4: Development of CXCR4 antagonist TNFα siRNA nanoparticles as an oral
treatment for IBD
4.1 Introduction
Traditional IBD therapy includes palliative medication like systemically given
anti-inflammatory and immunosuppressant drugs. Available evidence shows that IBD
arises from aberrant immune response and concurrent upregulation of pro-inflammatory
cytokines such as TNFα, IL-6 and IL-8. Success of treatments based on systemic
administration of anti-TNFα antibodies confirms that TNFα plays a prominent role in the
pathogenesis of IBD. However, TNFα inhibition exhibits a range of complications related
to the cost of the treatment and systemic immune suppression leading to a risk of
opportunistic infections and development of cancer. Chemokine receptor CXCR4 and its
ligand CXCL12 have also been implicated in the IBD pathology. The CXCR4/CXCL12 axis
is involved in regulating trafficking and invasion of inflammatory cells in the GI tract and
its inhibition is known to exert therapeutic effect in experimental IBD animal models.
Thus, both TNFα and CXCR4 are upregulated in IBD mucosa and represent an exciting
combination target for local IBD therapy. There is a great need for novel local treatments
of IBD as potentially safer alternatives to the current systemic treatments.
To better treat IBD, we sought to develop and test novel dual-function particles for
combination oral treatment designed to safely reduce colonic inflammation. The particles
are based on a recently developed polymeric CXCR4 antagonists (PCXA) designed to
encapsulate, protect, and orally deliver small interfering RNA (siRNA). We believe is that
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this combined approach will result in improved treatment of IBD as a result of decreased
inflammation due to TNFα siRNA (siTNF) and inhibition of CXCR4 by PCXA.
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Scheme 4.

Proposed mechanism of CS-PCXA-siRNA NPs.
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4.2 Materials and Methods
4.2.1 Materials
DSS (Mw 40,000) was obtained from TdB consultancy, DMEM, PBS, NaAc were
purchased from Thermo Fisher Scientific Inc., Cy5.5 labeled siRNA was bought from
Sigma Aldrich, Trizol reagent was purchased from Invitrogen, siTNFα and siSCR were
obtained from Dharmacon, CXCR4 redistribution assay kit was purchased from Thermo
Fisher Scientific Inc., CS was a kind gift from the lab of Dr. Kenneth Howard, Aarhus
University, Denmark, RAW 264.7 cells were obtained from the lab of Dr. Yuri
Lyubchenko.
4.2.2 Biodistribution of PCXA/siRNA particles in healthy mice
Mice were orally administered with PCXA/siRNA NPs. Cy5.5 labeled siRNA was
used with every mouse receiving 4 µg siRNA. The mice were sacrificed 24 h post
administration and the organs were harvested. Organs were visualized for fluorescence
using IVIS.
4.2.3 Therapeutic activity of PCXA
Colitis was induced in mice using 5% DSS solution. Mice were divided into
healthy controls, Untreated controls, PCXA i.p. and PCXA oral. After DSS treatment for
5 days, PCXA was administered either orally or i.p. three times a day for 3 days. The
longitudinally opened colons were rolled into a Swiss roll from distal to proximal end.
The rolls were fixed for 24 h in 4% paraformaldehyde, embedded in paraffin, sectioned
and stained with hematoxylin and eosin (H&E). The stained sections were evaluated by a
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pathologist without the knowledge of the identity of the samples using a light microscope.
Histopathological scores were assigned based on criteria as previously described. The
sections were graded based on ulceration, inflammation, crypt damage and edema. For
each tissue, a numerical score was assigned in a blinded manner to prevent bias. Scores
from each tissue section group were averaged to obtain a mean histopathological score.
4.2.4 Preparation and physical characterization of CS-PCXA-siRNA NPs
CS-PCXA-siRNA NPs were prepared by mixing CS, PCXA and siRNA solutions
(40:4:1) in 200mM NaAc buffer, pH 5.5 and vortexing for 30 seconds. This was followed
by incubation at room temperature for 20 minutes to stabilize the NPs before further use.
siRNA complexation in the NPs was studied by agarose gel electrophoresis. The prepared
NPs were loaded onto a 2% agarose gel containing 0.5 µg/ml ethidium bromide. Gels were
run in an assembly at 75 V in 0.5x Tris/Borate/EDTA (TBE) buffer for 45 minutes and
imaged under UV light using Kodak imager. The hydrodynamic radius of the NPs in
200mM NaAc buffer was measured using DLS. The results were expressed as mean ± SD
of three measurements.
4.2.5 Resistance to simulated fluids
To study the resistance of CS-PCXA-siRNA NPs against RNase I, 20 µl of NP
formulation containing a total amount of 0.2 µg siRNA were incubated with 2.5 units of
RNase I at 37 °C for 30 minutes. The mixture was further incubated at 90 °C for 30 minutes
to inactivate the enzyme. Heparin (200 µg/ml) was added to the samples and the mixtures
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were incubated at room temperature for 30 minutes to dissociate the siRNA. Agarose gel
electrophoresis was used to evaluate the siRNA integrity.
Resistance to SGF and SCF with bile salts was evaluated in a similar way. 20 µl of
NP formulations were incubated with 20 µl of either SGF or SCF respectively. The
mixtures were incubated at 37 °C for 30 minutes. Heparin was added and the mixtures
were incubated at room temperature for 30 minutes to dissociate the siRNA. Agarose gel
electrophoresis was used to evaluate the siRNA integrity.
4.2.6 CXCR4 inhibition assay
CXCR4 antagonism of the polycations and polyplexes was measured by CXCR4
redistribution assay using a high-contact fluorescence microscopy analysis. U2OS cells
stably expressing functional EGFP-CXCR4 fusion protein were seeded at a density of 8,000
cells/well in 96-well black plates with optical bottom 24 h before the experiment. On the
day of the assay, cells were washed twice with 100 µL assay buffer (DMEM supplemented
with 2 mM L-glutamine, 1% FBS, 1% Pen-Strep, and 10 mM HEPES) and incubated with
PCXA/siRNA, CS/siRNA, CS-PCXA/siRNA NPs or 300nM AMD3100 in triplicates in the
assay buffer containing 0.25% DMSO at 37 °C for 30 min. Then, 10 nM SDF-1 was added
to each well and the cells were incubated at 37 °C for 1 h. Cells were fixed with 4%
paraformaldehyde at room temperature for 20 min, washed 4 times with PBS and stained
in 1 µM Hoechst 33258 solution for 30 min before imaging (EVOS fl microscope).
4.2.7 Cellular uptake of CS-PCXA-siRNA NPs
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Cellular uptake of NPs was studied in RAW 264.7 mouse macrophage cell line.
Cells were seeded in 24-well plate at a density of 20,000 cells per well 24 h prior to the
study. 6-FAM labeled fluorescent siRNA (Sigma-Aldrich) was used. On the day of the
study, the cells were incubated with PCXA/siRNA, CS/siRNA and CS-PCXA/siRNA NPs
in serum free media at an siRNA concentration of 100nM. After 4 h incubation, the media
was removed. The cells were washed using cold PBS and scraped off using a cell scraper.
The cells were resuspended in PBS containing 10% FBS and analyzed for fluorescence
using flow cytometry. The results were processed using flow cytometry data analysis
software Flowjo and expressed as % 6-FAM positive cells ± SD.
RAW 264.7 cells were seeded in a 23-mm glass-bottom dish (Nioptechs Inc.) at a
density of 100,000 cells 24 h prior to study. 6-FAM labeled fluorescent siRNA was used.
On the day of the study, the cells were incubated with PCXA/siRNA, CS/siRNA and CSPCXA/siRNA NPs in serum free media at an siRNA concentration of 100nM. After 4 h
incubation, the media was removed. washed twice with PBS, fixed with 4%
paraformaldehyde, washed with PBS for additional 4 times and stained in 1 µM Hoechst
33258 solution. All the images were taken using Zeiss 710 confocal laser scanning
microscope equipped with a 63x oil objective and 4 lasers (Blue Diode 405 nm, Argon
458/488/514 nm, DPSS 561 nm and He-Ne 633 nm).
4.2.8 Mechanism of cellular uptake of CS-PCXA-siRNA NPs
Cells were seeded in 24-well plate at a density of 20,000 cells per well 24 h prior to
the study. On the day of experiment cells were pre-incubated for 30 minutes with various
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endocytotic inhibitors including chlorpromazine (10 µg/ml), genistein (200 µg/ml) and
wortmannin (50 nM). 6-FAM labeled fluorescent siRNA (Sigma-Aldrich) was used. On
the day of the study, the cells were incubated with CS-PCXA/siRNA NPs in serum free
media at an siRNA concentration of 100nM. After 4 h incubation, the media was removed.
The cells were washed using cold PBS and scraped off using a cell scraper. The cells were
resuspended in PBS containing 10% FBS and analyzed for fluorescence using flow
cytometry. The results were processed using flow cytometry data analysis software
Flowjo and expressed as % 6-FAM positive cells ± SD.
4.2.9 Selection of siRNA sequence
TNFα siRNA smartpool containing four different siRNA sequences from
Dharmacon was used. RAW 264.7 cells were seeded on 24-well plates at 5×104 cells/well
and cultured for 24 hours. Cell transfection was performed using Polyplyus
INTERFERIN® transfection reagent. For each well, 0.6 pmol of siRNA was diluted and
mixed in 100 µl serum-free DMEM. 2 µl of the transfection reagent was added to the
diluted siRNA and the mixture was homogenized by vortexing for 10 seconds. Similar
procedure was carried out to prepare complexes with scrambled siRNA. All the siRNA
sequences were used individually to form the transfection complexes. The complexes
were incubated at room temperature for 10 minutes to stabilize them. During this period,
500 µl of fresh DMEM containing 10 % FBS was added to the well having seeded cells. 100
µl transfection complexes were added to the wells and the plate was swirled gently to
allow homogenization. The final volume in the well was 600 µl with the siRNA
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concentration 1 nM. The plate was incubated at 37 °C for 24 hours before LPS stimulation
(100 ng/ml) for 6 h. TNFα mRNA levels were measured using RT-PCR and the fold
difference was calculated by ∆∆Ct method.
4.2.10 Biodistribution of CS-PCXA-siRNA NPs in mice
Male C57Bl6 mice, 6 weeks old were obtained from Charles river laboratories. 20
mice were kept as healthy mice. Colonic inflammation was induced using DSS or C.
rodentium as described below (20 mice in each group). NPs were prepared and 200 µl
formulation containing 30 µg Cy 5.5 labeled siRNA was administered to the mice. At predetermined timepoints, 5 mice from every group were sacrificed and the colon was
harvested, cleaned of feces and snap frozen in liquid nitrogen. The colons were
homogenized in RIPA buffer containing RNase inhibitor. The homogenate was
centrifuged for 15 minutes and 17,000 x g. 100 µl supernatant was pipetted into a 96-well
plate and fluorescence was measured using a 96-well plate reader comparing by standard
curve generated by diluting a known amount of siRNA with colon homogenate obtained
from control animals.
4.2.11 Effect of DSS on stability of CS-PCXA-siRNA NPs
CS-PCXA-siRNA NPs were prepared as previously described. The NPs were
incubated with varying concentrations of DSS for 30 minutes. The samples were run using
agarose gel electrophoresis and visualized under UV light to assess dissociation of siRNA
from the particles.
4.2.12 Efficacy of CS-PCXA-siRNA NPs in C. rodentium mouse model of colitis
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Inflammation was induced in male C57BL/6 mice, 6 weeks old using bacteria as
described before. Mice were divided into healthy controls, untreated controls (n=8), CSPCXA-siTNF and CS-PCXA-siSCR treated (n=5). Respective treatments were orally
administered to mice every other day over the 14 days of the model. On day 14, the mice
were sacrificed and the colons were harvested. On day 14, the mice were sacrificed and
the colons were harvested. The colon was opened longitudinally, cleaned of fecal matter,
and excised into two parts along the length, which were stored accordingly for
determination of cytokine mRNA levels by RT-PCR and histological analysis.
4.2.13 RT-PCR
Colon samples from the therapeutic study were stored in RNAlaterTM (Thermo
Fisher Scientific Inc.) at 4°C for 48 hours to allow sufficient time for tissue penetration
followed by removal of excess solution. The tissues were then stored at -80°C until further
processing. Stored frozen tissues were homogenized in TRIzolTM (Thermo Fisher Scientific
Inc.) reagent using TissueLyser II (Qiagen) and mRNA was isolated from the
homogenized tissues according to manufacturer’s protocol. The extracted mRNA was
quantified using Nanodrop Onec UV-Vis spectrophotometer (Thermo Fisher Scientific
Inc.). The cDNA was synthesized from the mRNA using High-Capacity cDNA Reverse
Transcription Kit with RNase Inhibitor per the manufacturer’s protocol (Thermo Fisher
Scientific Inc.). A volume corresponding to 1 µg of RNA as determined by UV
spectrometer was used for cDNA synthesis. Synthesized cDNA was stored at -20°C until
further use. RT-PCR was carried out using the synthesized cDNA from colon tissue
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samples to determine the levels of mRNA of the target genes. Healthy and untreated
colons were used as controls. cDNA was mixed with 0.2 µM primer pair for TNFα and
iTaqTM Universal SYBR® Green Supermix (Biorad) into an optical reaction tube (Qiagen).
The RT-PCR reaction was carried out in Rotor-Gene Q 2plex thermal cycler (Qiagen) using
the following cycle program: 95°C for 3 minutes; 40 cycles 60°C for 30 seconds. Results
obtained from the RT-PCR were analyzed by Ct method to determine the fold change in
gene expression.
4.2.14 Histological evaluation
The longitudinally opened colons were rolled into a Swiss roll from distal to
proximal end. The rolls were fixed for 24 h in 4% paraformaldehyde, embedded in
paraffin, sectioned and stained with hematoxylin and eosin (H&E). The stained sections
were evaluated by a pathologist without the knowledge of the identity of the samples
using a light microscope. Histopathological scores were assigned based on criteria as
previously described [165]. Scoring was performed based on severity of epithelial injury
(graded 0-3, from absent to mild including superficial epithelial injury, moderate
including focal erosions, and severe including multifocal erosions), the extent of
inflammatory cell infiltrate (graded 0-3, from absent to transmural), and goblet cell
depletion (0-1). For each tissue, a numerical score was assigned in a blinded manner to
prevent bias. Scores from each tissue section group were averaged to obtain a mean
histopathological score.
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4.3 Results and Discussion
The overall goal of this study was to develop NPs, made up of PCXA, CS and
siRNA. The particles should exhibit stability in the GIT and have improved uptake in the
colon when delivered orally.
4.3.1 Therapeutic activity of PCXA in DSS mouse model of colitis
Recently, the involvement of CXCR4 and its ligand CXCL12 in inflammation has
attracted significant interest. CXCR4 and its ligand CXCL12 were thought to be
exclusively involved in regulation of normal leukocyte recirculation and hematopoiesis.
However in recent years their involvement in inflammation has been realized [177].
CXCR4 and CXCL12 are expressed by cells in the normal intestinal mucosa, contributing
to cell migration. However, recently their presence has been extended to CXCR4+ lamina
propria T cells and pathogenesis of IBD [178, 179]. CXCR4 is overexpressed in inflamed
colons in humans as well as murine IBD models. Despite its important role in mediating
homeostasis, CXCR4 blockade has been attributed to reduction in inflammation in the
colon and intestinal tissue resurrection [180]. The ubiquitous expression of CXCR4 in the
inflamed intestines makes the CXCR4/CXCL12 axis blockade a promising therapeutic
strategy [144]. Unfortunately, chronic systemic administration of the only commercially
available CXCR4 antagonist AMD3100 has been associated with significant cardiotoxicity
thereby limiting its use as systemic IBD therapy [181, 182]. We have synthesized PCXA
which is a polymer of AMD3100 and shown its benefits in as a dual activity polymer
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which not only can inhibit CXCR4 but also complex nucleic acids. It was important to
assess whether the synthesized PCXA shows any therapeutic promise in IBD. To test that,
we conducted a preliminary study to investigate whether the anti-CXCR4 effect of PCXA
reduced inflammation in the DSS mouse model of colitis. Higher dose of orally delivered
PCXA was chosen to account for first pass metabolism. The results of the study are
represented in figure 20. As expected, the mice which received no treatment showed
significant inflammation and colon tissue damage elicited by the chemical injury due to
DSS. There was significant crypt damage, edema and infiltration by immune cells. As
opposed to the untreated controls, the groups which were administered PCXA showed
an improvement in the disease severity. The reduction in inflammation was evidenced
with higher number of intact crypts, presence of regular shaped goblet cells and
significantly less immune cell infiltration into the colon tissue. The histopathological
scores assigned to the H&E stained sections by a pathologist without the knowledge of
identity of samples are shown in figure. All the groups which received DSS showed a
significant increase in the inflammatory scores. However, the PCXA treated groups
showed a reduction in the inflammatory scores compared to the untreated group. This
indicated that the anti-CXCR4 activity of PCXA was reducing the colon inflammation. A
significant reduction in the inflammatory score was observed with the group where PCXA
was administered i.p. The group which received oral gavage of PCXA did not show a very
appreciable reduction in the inflammation. We attribute this poor effect with less colon
retention time for the orally administered PCXA. The PCXA administered i.p was
delivered directly at the site of inflammation and thus, showed a better therapeutic effect.
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In order to improve the GI retention time, we proposed the use of a mucoadhesive
polysaccharide, CS in the PCXA-siRNA NP formulation.
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Figure 20. Treatment of IBD with PCXA. Acute IBD was induced by 5% DSS in drinking
water and the mice were treated with i.p. or oral administration of PCXA (n=5). (a)
Representative H&E stained images of colon sections; (b) Histopathological scores.
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4.3.2 Biodistribution of PCXA/ siRNA particles in mice
After demonstrating the therapeutic promise of PCXA in a mouse model of IBD,
we investigated whether PCXA/siRNA NPs could deliver siRNA to the colon when
administered orally in healthy mice. Mice were gavaged with NPs and organs were
visualized ex vivo post-sacrifice using IVIS for signal from fluorescently labeled siRNA
(Fig. 21). Fluorescent signal for siRNA was observed in the colon 24 h post gavage.
Systemic organs like liver and spleen did not show any fluorescent signal. These results
gave us initial confidence that PCXA could deliver the siRNA to the colon via the oral
route and there was less systemic absorption of siRNA.
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Figure 21. Biodistribution of orally administered PCXA/siRNA NPs in mice. (1 – stomach,
2 – small intestine, 3 – large intestine, 4 – liver, 5 – kidneys, 6 – spleen, 7 – lung).
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4.3.3 Preparation of CS-PCXA-siRNA NPs
PCXA by itself can complex and condense siRNA into NPs. However, from our
previous studies, PCXA-siRNA NPs did not show significant delivery of siRNA in the
colon, probably due to stability issues as well as less retention time in the GIT.
Additionally, oral administration of PCXA did not show significant therapeutic effect in
a mouse model of colitis. These findings effected the need to modify the PCXA-siRNA NP
system to make it more compatible with oral administration. Various cationic carriers
have been investigated for the delivery of siRNA. Of all these CS has attracted
considerable research interest, especially in the oral delivery of siRNA. CS can bind to the
negatively charged siRNA to form NPs which can adhere to the negatively charged cell
membrane and be taken up via endocytosis. This helps to restrict the action of siRNA to
the colon which is desirable in a disease like IBD. Secondly, CS is available in a variety of
molecular weights and degrees of deacetylation. Based on our preliminary studies and
literature, we chose to use CS with molecular weight of 50 KDa and 80% degree of
deacetylation. However, CS is insoluble at neutral and alkaline pH. Hence, CS was
dissolved in 200 mM NaAc buffer, pH 4 at a concentration of 10 mg/ml and diluted further
to required concentrations in 200 mM NaAc buffer, pH 5.5.
CS, PCXA were used to complex siRNA resulting in the formation of NPs via
electrostatic interactions. This method prevents the use of heating or sonication, which
avoids interaction of siRNA with toxic organic solvents and maintains its biological
activity.
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4.3.4 Physical characterization of CS-PCXA-siRNA NPs
Based on preliminary experiments, NPs were prepared from CS: PCXA: siRNA in
the weight ratio of 40: 4: 1. Agarose gel electrophoresis was used to study the siRNA
complexation of the NPs. As shown in the figure 22a, CS-PCXA could completely complex
siRNA as evidenced by the absence of any free siRNA. This was expected at PCXA by
itself could complex siRNA at the concentration used. CS by itself does not possess
enough positive charge to completely complex siRNA. As a result, CS-siRNA showed
presence of some amount of free siRNA as seen in the figure.
The particles sizes and the zeta potentials of various NPs prepared were measured
using DLS and the results are expressed in figure 22b. All the NPs had diameters ranging
from 150 to 200 nm. The zeta potentials for all the particles were positive which was
expected because of all the cationic components used (not shown).
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Figure 22. Physicochemical characterization of NPs. (a) siRNA complexation in CS-PCXAsiRNA NPs by agarose gel electrophoresis; (b) Particle sizes in nm
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4.3.5 CXCR4 antagonistic activity
CXCL12 is the downstream signaling ligand for CXCR4. After binding it induces
downstream processes through multiple pathways line RAS and PI3 kinase. CXCR4
antagonists not only blocks the CXCL12-induced downstream signaling but also inhibits
endocytosis of the receptor [183]. To evaluate CXCR4 antagonism and to ensure that using
CS as such high concentrations would not hamper the anti-CXCR4 activity of PCXA,
CXCR4 redistribution assay was performed. The assay utilizes U2OS cells stably
expressing human CXCR4 receptor tagged to the N-terminal of enhanced GFP. The assay
monitors the cellular translocation of the GFP-CXCR4 receptors in response to stimulation
with human CXCL12. The cells received appropriate treatments followed by stimulation
with human CXCL12. As seen in figure 23, untreated cells exhibited the internalization of
CXCR4 receptors into the endosomes, as suggested by the punctate distribution of the
GFP fluorescence. On the contrary, treatment with AMD3100, a commercially available
CXCR4 antagonist blocked the internalization of the receptor as evidenced by no punctate
GFP fluorescence within the cells.
Next, we explored whether the NPs themselves exhibit CXCR4 antagonism. As
expected PCXA-siRNA NPs exhibited CXCR4 antagonism (Figure 23). On the other hand,
CS-siRNA NPs did not show any inhibition of CXCR4. This does not come as a surprise
as CS is not reported to have any anti-CXCR4 activity. The CXCR4 antagonism of CSPCXA-siRNA NPs was evaluated to make sure that CS which was at a concertation 10
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times higher than PCXA, did not affect the anti-CXCR4 activity of PCXA in any way. It
was observed that the CXCR4 inhibition for CS-PCXA-siRNA NPs was similar to the
inhibition observed with PCXA-siRNA NPs.
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Figure 23. CXCR4 inhibition of NPs. U2OS cells having GFP-tagged CXCR4 receptor were
treated with NPs followed by stimulation with SDF-1. Cells were observed under
fluorescence microscope. Untreated cells (0% CXCR4 antagonism), cells treated with 300
nM AMD3100 (100% CXCR4 antagonism).
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4.3.6 Resistance to biorelevant conditions
The structural integrity of NPs is important for the effective protection of their
payload. Orally delivered delivery systems face a lot of hurdles before they can reach the
colon. Few important factors include the volume of the digestive fluids, gastric juices, as
well as the alterations in the pH and the ionic strength which can result in damage to the
particle structure. Thus, assessing the stability of NPs against all these conditions forms
an important consideration for orally delivered therapeutics. Hence, we investigated the
effect of conditions which orally delivered systems usually encounter. We assessed the
effect of SGF and SCF on particle integrity using agarose gel electrophoresis after
incubating the NPs with SCF or SGF for 30 minutes. As seen from figure 24, siRNA
showed degradation in the SGF which is strongly acidic in nature. No effect on free siRNA
was observed in SCF which is close to a neutral pH. However, looking at all the NP
formulations, no change in the particle stability was observed as evidence in almost no
difference in the agarose gel bands compared to NP in formulation in buffer. No presence
of free siRNA was observed when the NPs were treated with either SCF or SGF indicating
no release of the siRNA cargo because of the conditions. This observation proved that the
particles maintained their structural conditions under the diverse pH as well as the salt
conditions commonly encountered in the GIT during transit.
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Figure 24. Stability of polyplexes to simulated gastric fluid (SGF) and simulated colonic
fluid (SCF). Formulations were incubated for 30 minutes with 30 µl SGF or SCF at 37oC.
Particle integrity was visualized using 2% agarose gel containing EtBr.
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The GIT is not only a diverse environment in terms of pH and ionic gradients, but also
in nucleases and other digestive enzymes. As a result, degradation of NP cargo is a
common concern. Degradation of siRNA results in loss of activity and to ensure
efficiency in vivo via oral delivery, siRNA must be protected from degradation either
by nuclease or by the ionic and pH conditions in the GIT. Upon confirmation that the
NPs maintained their structural integrity, we turned our attention to assessing the
integrity of the complexed siRNA under RNase, SGF and SCF conditions (Fig. 25).
Free siRNA and NPs were incubated with RNase, SGF and SCF, respectively for 1
hour. Post-incubation, heparin was to dissociate siRNA from the NPs and agarose gel
electrophoresis was used to assess the siRNA integrity. As seen from figure, free
siRNA treated with RNase and SGF was completely degraded, whereas clear siRNA
band was observed after incubation with SCF. This suggested that siRNA was mainly
degraded in the stomach due to the gastric juices and in presence of RNase while
remaining comparatively intact in the colon. siRNA loaded into PCXA-siRNA NPs
showed faint bands compared to free siRNA indicating partial degradation. On the
contrary, CS-siRNA and CS-PCXA-siRNA NPs showed bright bands which were
comparable in intensity to free siRNA bands suggesting that they provided good
protection for their payload which correlated with the results of structural stability of
NPs. No degradation of complexed siRNA was observed in the SCF which was
expected from the fact that even free siRNA did not show any degradation under
those conditions. These results might suggest that PCXA was not bulky compared to
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chitosan which could prevent nucleases and other potential degradants from
approaching siRNA via steric hindrance. This study proves the utility of both our
cationic components where PCXA acts as a strong complexing agent as opposed to
chitosan which provides complexation, in addition to making the NP system more
amenable to oral delivery of siRNA by providing protection.
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Figure 25. siRNA protection ability of NPs. Formulations were incubated for 30 minutes
with 20 µg/ml RNase, 30 µl SGF or SCF at 37oC. siRNA was displaced by heparin and its
integrity was visualized using 2% agarose gel containing EtBr.
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4.3.7 Cellular uptake of NPs
Efficient cellular uptake is a pre-requisite for the therapeutic effect of siRNA. To
determine the uptake of the NPs, RAW 264.7 cells were incubated with PCXA-siRNA, CSsiRNA and CS-PCXA-siRNA NPs containing fluorescent siRNA in serum free conditions,
respectively. RAW 264.7 cells are a mouse derived macrophage cell line and are relevant
to this study as our target cells for siRNA delivery are the immune cells which infiltrate
the colonic epithelium. After 4 hours, the percentage of cells expressing fluorescence was
quantified by flow cytometry. Binding of particles to the cell surface and giving a
fluorescence signal is always a concern with NP uptake with flow cytometry. This results
in a false positive fluorescence signal. To overcome this limitation, the cells were
resuspended in flow buffer containing trypan blue to quench the fluorescence from the
particles binding to the cell surface as well as eliminating any dead cell population from
the uptake analysis (Fig. 26a). As seen from figure, cells incubated with free siRNA did
not show a significant fluorescent signal. Similarly, PCXA-siRNA NPs did not show a
significant increase in the uptake as compared to free siRNA. The inclusion of CS in the
formulation significantly increased the uptake of NPs. Almost 40 % of the cells treated
with CS-siRNA NPs showed a fluorescent signal. However, CS-PCXA-siRNA NPs,
showed the highest signal with approximately 60 % of the cells showing fluorescence.
We visualized the uptake of CS-PCXA-siRNA NPs using confocal microscopy (Fig
26b). Our observations on the confocal microscope images correlated with the findings
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with flow cytometry. The cellular uptake is shown in figure. We also took Z-stack images
at various depths within the cells and observed that majority of the particles were
internalized by the cells and not stuck to the cell surface (Fig. 27). This proved that our
formulation not only possessed the physicochemical properties to complex and protect
siRNA in the GIT on oral delivery, but also could deliver siRNA inside the macrophages
which are the target cells for most of the anti-inflammatory IBD therapies.
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Figure 26. Cellular uptake of NPs. RAW 264.7 mouse macrophages were treated in serumfree media with polyplexes containing siRNA labeled with 6-FAM. Uptake was quantified
by (a) flow cytometry and visualized by (b) confocal microscopy. Flow cytometry results
expressed as percent 6-FAM positive cells ± SD (n=6).
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Figure 27. Z-stack images of cellular uptake of CS-PCXA-siRNA NPs. Image slices were
taken at various depths in the cells to ensure internalization of particles.
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4.3.8 Mechanism of cellular uptake of CS-PCXA-siRNA NPs
Upon confirmation of enhanced uptake of CS-PCXA-siRNA NPs by macrophages,
we turned our attention to the mechanism for the uptake of the NPs. An efficient uptake
of NPs is essential for the intracellular delivery of cargo [184]. RAW 264.7 cells are
reported to express CXCR4 receptor [185]. Hence, the first goal was to identify if the
uptake we observed was because of the ability to target CXCR4 receptor. We incubated
RAW 264.7 cells with various concentrations of AMD as well as PCXA (not shown) for 30
minutes before quantifying for cellular uptake by flow cytometry. We observed no
significant decrease in the uptake of the NPs after incubation with AMD (Fig. 28a). We
also incubated cells with free PCXA, however, did not observe any reduction in the uptake
of NPs. This proved that the uptake was not CXCR4 mediated and some other endocytosis
mechanism was involved in the NP uptake by the cells.
To explore other mechanisms, we incubated RAW 264.7 cells with inhibitors of
various endocytotic processes (Fig. 28b). It was made sure that the inhibitors were not
toxic to the cells in the used concentrations (not shown). After incubation for 30 minutes,
the cells were treated with CS-PCXA-siRNA NPs having 6-FAM labeled siRNA. The
uptake was quantified using flow cytometry. We observed no decrease in the NP uptake
for cells treated with CPZ and WRT. CPZ and WRT inhibit caveolin and clathrin-mediated
endocytosis, respectively. Hence both these processed did not seem to be involved in the
uptake of the NPs. However, a significant decrease in the uptake was observed for GEN
treated cells. GEN is a specific inhibitor of micropinocytosis. Almost 30 % reduction in the
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uptake was observed when micropinocytosis was inhibited which points out that it might
be involved to a considerable degree in the uptake of these particles by macrophages.
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Figure 28. Mechanism of cellular uptake. Cells were treated for 30 minutes serum-free
media with (a) AMD3100 and (b) various endocytic inhibitors and then with NPs
containing 6-FAM-siRNA. Uptake was quantified by flow cytometry. Results expressed
as percent 6-FAM positive cells (n=3).
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4.3.9 Selection of siTNFα sequence
We used the smartpool siRNA commercially available from Dharmacon to choose a
sequence which could efficiently silence TNFα. Four individual sequences and a mixture
of the four siRNAs was used for the screening. We carried out our experiments in RAW
264.7 mouse macrophages which were treated with the respective siRNAs and then
stimulated with LPS to induce TNFα 24 h later. Fold change in TNFα mRNA expression
results determined by RT-PCR are shown in figure 29. As compared to the control cells,
the cells treated with LPS showed almost 30-fold increase in TNFα expression. This
proved that the LPS stimulation was working and upregulating the TNFα levels. The cells
treated with the scrambled siRNA sequence showed TNFα mRNA levels similar to the
untreated control cells indicating that the scrambled siRNA or the formulation
components by itself did not affect the expression of TNFα in anyway. The cells treated
with the siRNA mixture showed 20-fold increase in the expression as opposed to 30-fold
upregulation seen in the untreated cells indicating that some sequence in the mixture was
silencing TNFα. On testing individual sequences, we observed that sequences 1 and 2 did
not show any downregulation of TNFα. However, sequences 3 and 4 showed significant
TNFα silencing compared to untreated control. Sequence 3 was the best performing
amongst the four siRNAs. Hence, we chose that sequence for our further experiments.

TNF mRNA level
(relative to control cells)
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Figure 29. Selection of TNFα siRNA sequence. RAW 264.7 cells were treated with Polyplus
transfection reagent-siRNA complexes. Different sequences of siRNA obtained from
Dharmacon were used. 24h post treatment, cells were stimulated with LPS. TNFα mRNA
levels were measured using RT-PCR. Results expressed as fold change in TNFα mRNA
levels ± SD (n=6).
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4.3.10 Biodistribution of CS-PCXA-siRNA NPs in mice
We assessed the biodistribution of our NPs to make sure that the particles were
stable in vivo and were delivering the siRNA to the colon (Fig. 30). We evaluated the
siRNA biodistribution in healthy as well as both the mouse models described in this
dissertation. When assessed for biodistribution, the healthy mice showed fluorescence
signal from 0.5 h post administration with about a 50 % reduction in signal at 12 h (Fig.
30a). In the C. rodentium model, the fluorescence signal was observed at 30 minutes (Fig.
30b). However, it diminished significantly within 2 h. This may probably be due to the
presence of diarrhea and the formulation might be lost due to the less transit time. We
were surprised to find that in the DSS model, no signal was observed. This finding might
indicate that DSS which is a strong polyanion might be interacting with the NPs causing
the dissociation and degradation of siRNA in the GIT. Secondly, it has been reported that
DSS is deposited onto the mucosal surfaces resulting in formation of barrier that might
interfere with the interaction of the delivery system with the tissue. Although,
fluorescence is not a very quantitative method to quantify siRNA in vivo, this study gave
us confidence that the NPs were delivering siRNA to the colon in sick animals. As a result,
we proceeded to test the efficacy of these particles in vivo in C. rodentium mouse model of
colitis.
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Figure 30. Biodistribution of siRNA in vivo. Mice were gavaged with CS-PCXA-siRNA
NPs containing 30 µg Cy5.5 labeled siRNA and fluorescence signal in colon supernatant
was measured at different timepoints in (a) Healthy mice; (b) Mice with C. rodentium
induced colitis. Results are expressed as µg siRNA/ g of tissue ± SD (n=5).
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4.3.11 Effect of DSS on stability of CS-PCXA-siRNA NPs
Looking at the mouse biodistribution data, we assessed the effect of DSS on the
stability of NPs in vitro (Fig. 31). The results for the stability studies are represented in
figure. We observed that with increasing concentrations of DSS, the particles began to lose
their integrity. We observed displacement of siRNA from DSS concentration as low as 50
µg/ml. Complete dissociation of siRNA from the NPs was observed at a DSS concentration
of 500 µg/ml. This correlated with our biodistribution studies in vivo where the particles
did not show any signal in the colon of mice which were on DSS. The DSS concentrations
at which the siRNA was being displaced were significantly lower than the concentrations
that would be found in mice which were having DSS in their water. This confirmed our
hypothesis that DSS because of its strong polyanionic nature was destabilizing the
particles leading to premature release and degradation of siRNA in the GIT leading to no
therapeutic effect. DSS is reported to exert its action by forming lipid vesicles with fatty
acids in the GI lumen indicating its potential to interact electrostatically [143]. Also, DSS
colon deposition studies have shown that DSS is deposited on the epithelium surface
essentially forming a barrier between the delivery systems and the inflamed tissue [186].
All these factors make the use of DSS model of colitis an important consideration,
especially when charge based delivery systems are involved.
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Figure 31. Effect of DSS on stability of NPs. CS-PCXA-siRNA NPs were incubated for 30
minutes with increasing concentrations of DSS. siRNA was visualized using agarose gel
electrophoresis.
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4.3.12 Efficacy of CS-PCXA- siTNFα NPs in C. rodentium mouse model of colitis
Encouraged by the colonic delivery of siRNA, we tested the efficacy of our NPs in
colitis. We assessed the therapeutic efficacy of CS-PCXA-siTNF particles in vivo. The mice
affected with colitis were treated with oral gavage of CS-PCXA-siTNF or CS-PCXA-siSCR
NPs every other day. Histological changes in the colon were observed post animal
sacrifice on day 14.
We also assessed the TNFα silencing in the colon using RT-PCR (Fig. 32).
Upregulation of pro-inflammatory cytokines is a hallmark of IBD. TNFα plays a major
role in inflammatory response and has been successfully explored as a major therapeutic
target in IBD. TNFα plays a prominent role in IBD due to its contribution to the
recruitment of immunocompetent cells that amplify the inflammatory response in T cells,
macrophages, and mucosal cells [187, 188]. TNFα also has damaging effects on tight
junctions, impairing barrier function, and enhancing the immune challenge by luminal
antigens [189]. TNFα levels are increased in both serum and mucosa of IBD patients as
well as in mouse models of IBD [190-192]. Consequently, blockade of TNFα can
significantly improve or even prevent inflammation in both humans with IBD and animal
IBD models. In addition to the successful use of systemic TNFα neutralization with
antibodies [193], local TNFα gene silencing in the inflamed mucosa with antisense
oligonucleotides and siRNA represents a promising alternative to attenuate IBD [194-199].
On day 14, we assessed the levels of TNFα mRNA in colon. Colons of untreated mice
showed almost six-fold upregulation in TNFα as compared to healthy control mice. Not
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much difference was observed between untreated group and the group which was treated
with CS-PCXA-siSCR NPs. However, a significant difference was observed between the
mRNA levels between the untreated and the CS-PCXA-siTNF treated group. The
difference translated to almost a 40% TNFα silencing. However, the difference in mRNA
levels between the CS-PCXA-siTNF and CS-PCXA-siSCR treated group was not found to
be significant.
We assessed the histopathology of colons from the NP treated mice (Fig. 33). We
found a significant reduction in the crypt length in the colons of mice who were treated
with CS-PCXA-siTNF NPs compared to untreated as well as the mice treated with the
NPs having the siSCR control (Fig. 33b). Significant reduction was observed in the
histopathological scores for the NP treated mice compared to the sick control (Fig. 33c).
However, no significant difference was observed in the scores between mice treated with
NP containing siTNF versus those containing siSCR.
As a result, although we were able to deliver siRNA as well as saw reduction in
the TNFα mRNA levels, the silencing was probably not significant enough to contribute
to reduction in the inflammation. The observed reduction in the inflammatory scores
seemed to be majorly due to CXCR4 inhibition by PCXA.
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Figure 32. Effect of CS-PCXA-siTNF NPs on murine colonic TNFα mRNA levels. Fold
change in colonic TNFα mRNA expression relative to healthy control. Data are
represented as mean ± SD.
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Figure 33. Therapeutic effect of CS-PCXA-siTNF NPs in C. rodentium model of colitis. (a)
Representative H&E stained colon section images; (b) colon crypt length; (c) Histological
scores.

138

4.4 Conclusion
We have demonstrated that CS-PCXA-siRNA particles are amenable to oral
administration and subsequent delivery to the colon. We showed this by proving that
these particles protect the siRNA from degradation in the GIT. Our biosdistribution
studies point out the ability of these particles to deliver siRNA into the colon. We have
shown in vivo that CXCR4 inhibition by PCXA has a therapeutic advantage in treating
inflammation in the colon as well as shown gene silencing. Future efforts are needed to
improve the formulation and enhance the anti-inflammatory effect.
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CHAPTER 5: SUMMARY
IBD is a chronic inflammatory disorder which necessitates the patient to be on
therapy almost life-long. Due to limitations like severe systemic side effects, current IBD
therapy faces many hurdles. As the inflammation in IBD is local and confined to the GI
tissue, therapies which can deliver drugs safely and locally are preferred. However, there
is a lack of delivery systems that can achieve high local bioavailability of drugs. We tried
to address this problem in this dissertation by developing delivery systems that can show
preferential accumulation in the colon and improve therapeutic outcomes in IBD.
PDCs have been reported a lot in the treatment of many diseases. The advantage
of a PDC is that it can change the properties of the drug to make it more suited to a
particular physiological environment. Most of the reported PDCs for delivery to the colon
have been synthesized with a goal of specific dissociation of drug under colonic pH.
Although this strategy works for protecting the drug in the gastric environment, once
released in the colonic environment, the drug still shows high systemic absorption which
is not desirable from in treating local inflammation as well as from a safety perspective
for some drugs. We selected CQ which is a widely used drug and has been in the clinics
for a very long time. It has limited application as an anti-inflammatory agent and is an
example of drug which shows high systemic absorption and long term side effects when
administered orally. We synthesized a non-cleavable PDC of CQ to form pCQ. We
showed that pCQ not only accumulates specifically in the GIT showing similar antiinflammatory effects at HCQ, but also shows almost 1000-fold reduction in systemic
absorption which is an indication of improved safety profile. We proved that by utilizing
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this strategy we can make CQ amenable to multiple dosing which is difficult with the
small molecule drug as it shows side effects like retinopathy after long term use. We
proved all these findings in an animal model of colitis.
Secondly, we also investigated combination delivery of siRNA and a polymeric
inhibitor of CXCR4 using mucoadhesive NPs. We found that although PCXA could
deliver siRNA to the colon, it did not exert significant anti-inflammatory effect when
administered orally. In order to increase the retention of PCXA-siRNA NPs, we included
mucoadhesive polysaccharide CS to prepare CS-PCXA-siRNA NPs. We have shown that
these nanoparticles were stable in simulated GI fluids as well as could protect siRNA
against these fluids and RNase. Lastly, we have shown that we could achieve therapeutic
effect through CXCR4 inhibition by PCXA and gene silencing by TNFα in a mouse model
of colitis.
All these findings take a step in the direction of development of systems that can
deliver therapeutics locally to the colon to treat inflammation. Our on-going efforts are
focusing on improving both the above described formulations. We plan to formulate pCQ
as particles and have performed preliminary testing which shows improved uptake into
the colonic tissue for pCQ particles. Future efforts for CS-PCXA-siRNA particles will
involve improving the inflamed tissue specificity as well as exploring novel targets.
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